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Abstract 
 
 
 
Context:  Cardiovascular  diseases  are  the  leading  cause  of  death  
globally.  Myocardial  infarction  is  responsible  for  the  highest  number  of  
deaths  due  to  cardiovascular  disease. 
Objective:  We  have  previously  shown  that  acute  benfotiamine  
administration  at  the  onset  of  reperfusion  is  associated  with  decreased  
infarct  size  and  preserved  contractile  function  in  response  to  
ischemia-reperfusion.  We  aimed  to  evaluate  the  involvement  of  the  
phosphatidylinositol  3-kinase/Akt  (PI3K/Akt)  and  Janus  kinase/signal  transducer  
and  activator  of  transcription  (JAK/STAT)  pro-survival  signaling  pathways  in  
mediating  these  cardioprotective  effects. 
Materials  and  Methods:  Part  One  -  Hearts  were  rapidly  excised  
from  Wistar  rats  and  mounted  on  a  Langendorff  perfusion  apparatus.  After  
stabilization,  hearts  were  subjected  to  30  minutes  of  regional  ischemia  and  
120  minutes  of  reperfusion.  The  control  group  received  no  treatment.  
Experimental  groups  were  treated  with  100 μM  benfotiamine  ±  0.1 μM  
Tyrphostin  AG490  or  Wortmannin  (inhibitors  of  JAK2  and  PI3K,  
respectively),  dissolved  in  dimethyl  sulfoxide.  The  vehicle  control  group  
received  an  equivalent  dose  of  dimethyl  sulfoxide.  All  treatments  were  
administered  for  20  minutes  at  the  onset  of  reperfusion.  Functional  
parameters  were  measured  throughout,  to  test  the  effects  of  benfotiamine  
±  pro-survival  pathway  inhibitors  on  functional  recovery.  In  addition,  hearts  
were  stained  with  Evans  blue  and  triphenyltetrazolium  chloride  to  assess  
the  effects  of  benfotiamine  ±  pro-survival  pathway  inhibitors  on  infarct  size.   
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Part  Two  -  Hearts  that  were  perfused  ±  30  minutes  of  global  
ischemia  and  ±  20  minutes  of  benfotiamine  administration,  were  used  to  
assess  PI3K/Akt  and  JAK/STAT  signaling  in  response  to  ischemia-reperfusion  
and  benfotiamine  treatment.  As  with  previous  experiments,  benfotiamine  was  
administered  at  a  concentration  of  100 μM,  at  the  onset  of  reperfusion.  
Tissues  were  assessed  by  Western  blot  analysis. 
Results:  20  minutes  of  acute  benfotiamine  administration  at  the  
onset  of  reperfusion  led  to  a  decrease  in  infarct  size  (35.6  ±  2.4%  vs.  55.7  
±  5.0%  [p<0.05]).  Inhibition  of  PI3K/Akt  signaling  by  addition  of  
Wortmannin  abrogated  this  infarct-limiting  effect  (51.5  ±  1.3%  vs.  35.6  ±  
2.4%  [p<0.05]).  However,  inhibition  of  JAK/STAT  signaling  had  no  effect.  
There  were  no  significant  differences  in  left  ventricular  developed  pressure,  
coronary  flow  rate  or  heart  rate  during  the  experiments. 
In  addition,  20  minutes  of  acute  benfotiamine  administration  at  the  
onset  of  reperfusion  lead  to  an  increase  in  phospho-FOXO/FOXO  in  the  
cytosolic  fraction,  but  no  significant  change  in  phospho-STAT3/STAT3  in  the  
nucleus. 
Conclusions:  Our  results  suggest  that  acute  benfotiamine  
administration  at  the  onset  of  reperfusion  may  act  to  reduce  infarct  size  
via  activation  of  PI3K/Akt  pro-survival  signaling.  
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Opsomming 
 
 
 
Konteks:  Kardiovaskulêre  siekte  is  die  hoofoorsaak  van  sterftes  
wêreldwyd.  Miokardiale  infarksie  is  verantwoordelik  vir  die  grootste  aantal  
sterftes  weens  kardiovaskulêre  siekte.   
Doel:  Ons  het  voorheen  getoon  dat  akute  benfotiamientoediening  
met  die  aanvang  van  reperfusie  geassosieer  is  met  „n  verkleining  in  die  
infarkgrootte,  en  dit  het  verder  ook  die  kontraktiele  funksie  in  reaksie  op  
ischemie-reperfusie  behou.  Ons  doel  was  om  die  betrokkenheid  van  die  
fosfatidielinositol  3-kinase/Akt  (PI3K/Akt)  en  Janus  kinase/seintransduseerde  en  
aktiveerder  van  transkripsie  (JAK/STAT)  pro-oorlewings  seinweg  in  die  
mediasie  van  hierdie  kardiobeskermende  effekte  te  evalueer.   
Materiale  en  Metodes:  Deel  een  -  Harte  is  vinnig  vanuit  
Wistarrotte  verwyder  en  op  die  Langendorff-perfusieapparaat  gemonteer.  Na  
stabilisering  is  die  harte  blootsgestel  aan  30  minute  regionale  ischemie  en  
120  minute  reperfusie.  Die  kontrole  groep  het  geen  behandeling  ontvang  
nie.  Eksperimentele  groepe  is  met  100 μM  benfotiamien  ±  0.1  μM  Tirfostien  
AG490  of  Wortmannin  (inhibeerders  van  JAK2  en  PI3K,  onderskeidelik)  
behandel,  opgelos  in  dimetielsulfoksied.  Die  draer-kontrole  groep  het  „n  
ekwivalente  dosis  van  dimetielsulfoksied  ontvang.  Alle  behandelings  is  
toegedien  vir  20  minute  aan  die  begin  van  die  reperfusie.  Funksionele  
parameters  is  deurgaans  gemeet  om  te  toets  vir  die  effekte  van  
benfotiamien  ±  pro-oorlewingsweg  inhibeerders  op  funksionele  herstel.  
Verder  is  die  harte  met  Evans-blou  en  trifenieltetrazoliumchloried  gekleur  
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om  die  effek  van  benfotiamien  ±  pro-oorlewingsweg  inhibeerders  op  die  
infarkgrootte  te  bepaal. 
Deel  twee  -  Harte  is  vir  ±  30  minute  perfuseer  met  globale  ischemie  
en  ±  20  minute  met  benfotiamientoediening.  Dit  was  gebruik  om  PI3K/Akt  
en  JAK/STAT  seine  as  gevolg  van  ischemie-reperfusie  en  
benfotiamienbehandeling  te  ondersoek.  Soos  met  die  vorige  eksperimente,  is  
benfotiamien  toegedien  by  ‟n  konsentrasie  van  100 μM  met  die  aanvang  van  
reperfusie.  Weefsel  is  ondersoek  deur  middel  van  Western  blot  analise. 
Resultate:  20  minute  van  akute  benfotiamientoediening,  met  die  
aanvang  van  reperfusie,  het  tot  „n  verkleining  in  die  infarkgrootte  (35.6  ±  
2.4%  vs.  55.7  ±  5.0%  [p<0.05])  gelei.  Inhibering  van  die  PI3K/Akt  seinweg  
deur  toediening  van  Wortmannin  het  die  infark-beperkende  effek  opgehef  
(51.5  ±  1.3%  vs.  35.6  ±  2.4%  [p<0.05]).  Inhibering  van  JAK/STAT  seine  het  
egter  geen  effek  getoon  nie.  Daar  was  geen  beduidende  verskille  in  
linkerventrikulêr-ontwikkelde druk,  koronêre-vloeitempo  of  harttempo  tydens  
die  eksperimente  nie. 
Verder,  20  minute  van  akute  benfotiamientoediening  met  die  aanvang  
van  reperfusie  het  „n  toename  in  fosfo-FOXO/FOXO  in  die  
sitosoliese-fraksie  veroorsaak,  maar  geen  beduidende  verandering  in  
fosfo-STAT3/STAT3  is  in  die  nukleus  waargeneem  nie. 
Gevolgtrekkings:  Ons  resultate  suggereer  dat  akute  
benfotiamientoediening  met  die  aanvang  van  reperfusie  moontlik  die  
infarkgrootte  via  aktivering  van  die  PI3K/Akt  pro-oorlewingsein  kan  verklein.  
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CHAPTER  ONE:  Introduction 
 
 
  
 
Cardiovascular  diseases  are  the  leading  cause  of  death  globally1.  
Myocardial  infarction,  commonly  known  as  a  heart  attack,  accounts  for  the  
highest  number  of  deaths  due  to  cardiovascular  diseases2.  Despite  
improvements  in  patient  care  and  the  use  of  current  treatments,  millions  of  
deaths  continue  to  occur  annually  as  result  of  myocardial  infarction3.  The  
treatment  of  cardiovascular  disease  and  its  consequences  imposes  a  
significant  financial  burden  upon  individuals  and  national  economies,  hindering  
development  in  low-  and  middle-income  countries4.  This  burden  is  predicted  
to  increase,  as  globalization  and  urbanization  contribute  to  an  increased  
prevalence  of  cardiovascular  disease  risk  factors5.  Therefore,  an  urgent  need  
exists  for  effective,  low-cost  treatments  for  myocardial  infarction. 
The  death  of  cardiac  cells  is  a  major  consequence  of  myocardial  
infarction  that  can  result  in  significantly  impaired  contractile  function.  
Ischemic  postconditioning  (hereinafter  referred  to  as  „postconditioning‟)  is  a  
strategy  employed  to  limit  cardiac  cell  death  that  was  first  described  in  
20036.  Although  it  has  been  applied  successfully  in  small-scale  clinical  trials7,  
it  is  not  without  its  limitations.  For  example,  its  benefit  is  compromised  by  
age  and  the  presence  of  comorbidities  such  as  diabetes  and  high  blood  
pressure,  both  of  which  are  common  in  patients  being  treated  for  
myocardial  infarction8.  As  a  result  of  its  limited  applicability,  researchers  
began  investigating  the  underlying  mechanisms  of  postconditioning.  These  
studies  focused  on  the  pro-survival  pathways  activated  in  the  heart  by  
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postconditioning.  Their  aim  was  to  find  alternative  means  of  conferring  
cardioprotection  by  targeting  these  pathways  pharmacologically.  The  
investigation  into  this  new  strategy  of  „pharmacological  postconditioning‟  
sparked  further  interest  in  the  field  of  cardiac  cell  signaling. 
The  phosphatidylinositol  3-kinase  (PI3K)/Akt  pathway  and  the  Janus  
kinase  (JAK)/signal  transducer  and  activator  of  transcription  (STAT)  pathway  
are  two  pro-survival  signaling  pathways  that  are  activated  during  myocardial  
infarction9,10.  Both  of  these  pathways  participate  in  mediating  the  
cardioprotective  effects  of  postconditioning11. 
Recent  work  by  ourselves  and  others  found  that  benfotiamine,  a  
vitamin  B1  derivative,  may  have  therapeutic  potential  in  treating  myocardial  
infarction12,13.  Moreover,  we  found  that  these  cardioprotective  effects  could  
be  induced  by  acute  benfotiamine  administration  at  the  onset  of  
reperfusion.  However,  our  initial  study  left  unanswered  questions  regarding  
the  underlying  mechanisms  of  these  effects.  As  a  result,  we  decided  to  
investigate  the  involvement  of  the  PI3K/Akt  and  JAK/STAT  signaling  
pathways  in  mediating  benfotiamine‟s  effects. 
In  order  to  provide  a  theoretical  framework  for  the  study,  the  
following  chapter  will  draw  attention  to  relevant  aspects  of  the  literature  
concerning  cell  signaling  in  the  heart.  In  addition,  it  will  describe  the  
discovery  of  benfotiamine  and  discuss  its  therapeutic  potential  in  the  heart.  
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CHAPTER  TWO:  Literature  Review 
 
 
 
 
The  first  part  of  this  chapter  focuses  on  the  PI3K/Akt  and  
JAK/STAT  signaling  pathways:  a)  their  role  in  mediating  the  cell‟s  response  
to  threat,  b)  their  involvement  in  postconditioning  and  c)  the  pursuit  of  
pharmacological  means  to  activate  them.  The  second  part  of  the  chapter  
will  take  a  closer  look  at  benfotiamine  -  a  therapeutic  agent  that  may  
activate  these  pathways.  In  this  section:  a)  its  discovery  will  be  described,  
b)  its  therapeutic  potential  in  protecting  the  heart  from  hyperglycemia  and  
myocardial  infarction  will  be  discussed,  and  c)  its  potential  as  a  
pharmacological  postconditioning  agent  will  be  explored. 
  
1.  Cell  signaling 
The  functioning  of  a  cell  relies  on  its  ability  to  perceive  changes  in  
its  microenvironment  and  respond  accordingly.  In  addition,  it  must  be  able  
to  send  and  receive  messages  from  neighboring  or  distant  cells.  This  is  a  
crucial  feature  of  cells  comprising  multicellular  organisms  –  the  capacity  to  
cooperate14.  These  cells  must  communicate  during  growth  and  development.  
In  addition,  they  must  work  together  to  maintain  homeostasis  and  respond  
to  tissue  damage  or  disease. 
When  exposed  to  a  threat,  cells  can  employ  any  one  of  a  range  of  
survival  mechanisms.  For  example,  they  can  respond  by  rapidly  synthesizing  
and  secreting  soluble  proteins  called  cytokines.  These  cytokines  inform  
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surrounding  cells  of  the  threat  and  recruit  assistance  in  managing  it.  
Cytokines  are  „perceived‟  by  neighboring  cells  via  specific  cytokine  receptors  
embedded  in  their  cell  membranes.  This  message  is  then  transmitted  to  the  
nucleus  via  intracellular  signaling  pathways  such  as  the  JAK/STAT  pathway15.   
The  nucleus  orchestrates  a  cellular  response  to  this  message  by  
altering  the  expression  of  specific  genes.  The  level  of  expression  of  specific  
genes  can  be  increased  or  decreased  in  order  to  facilitate  cell  survival  and  
adaptation  to  current  conditions.  For  example,  JAK/STAT  signaling  is  
associated  with  upregulation  of  genes  that  promote  cell  survival,  and  
downregulation  of  genes  that  promote  cell  death16.  In  addition  to  enabling  
survival  and  adaptation,  gene  expression  can  be  altered  to  enable  cells  to  
actively  counteract  the  threat  and  attempt  to  restore  homeostasis.  For  
example,  JAK/STAT  signaling  is  associated  with  increased  expression  of  
genes  that  promote  angiogenesis,  the  formation  of  new  blood  vessels17.  
Thus,  a  cell  can  initiate  a  survival  mechanism  in  neighboring  cells,  which  
involves  JAK/STAT  signaling  and  altered  gene  expression. 
However,  altered  gene  expression  is  not  the  only  weapon  in  the  
cell‟s  arsenal.  A  second  survival  mechanism  that  cells  can  employ  involves  
the  mitochondrion,  which  plays  a  crucial  role  in  regulating  cell  death.    
When  exposed  to  a  threat,  cells  can  activate  this  survival  mechanism  in  
surrounding  cells  by  releasing  substances  such  as  adenosine18.  When  
adenosine  binds  to  the  membrane-embedded  receptors  of  surrounding  cells,  
it  leads  to  a  variety  of  effects  including  the  initiation  of  signaling  via  the  
PI3K/Akt  signaling  pathway19.   
The  activation  of  PI3K/Akt  signaling  allows  for  rapid,  transient  
adaptations  such  as  the  post-translational  modification  of  existing  proteins,  
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thereby  altering  their  function.  For  example,  by  phosphorylating  specific  
proteins  associated  with  the  mitochondrion,  PI3K/Akt  signaling  can  prevent  
cell  death20.  Thus,  a  cell  can  initiate  a  survival  mechanism  in  neighboring  
cells,  which  involves  PI3K/Akt  signaling  and  the  post-translational  modification  
of  mitochondrial  proteins. 
Both  of  these  survival  mechanisms  (altered  gene  expression  and  
post-translational  modification  of  mitochondrial  proteins)  are  essential,  since  
they  act  at  the  nucleus  and  mitochondria,  key  coordinators  of  cellular  
function  and  cell  death.  The  response  of  cardiac  cells  during  myocardial  
infarction  is  a  pertinent  example  of  the  how  initiating  signaling  via  the  
JAK/STAT  and  PI3K/Akt  signaling  pathways  allows  cells  to  respond  to  a  
threat.  The  following  section  will  briefly  describe  the  pathology  of  
myocardial  infarction  and  discuss  the  role  of  these  pathways  in  responding  
to  it. 
 
2.  The  activation  of  endogenous  survival  mechanisms  during  myocardial  
infarction  
Myocardial  infarction  occurs  when  the  blood  supply  to  a  particular  
region  of  the  heart  is  interrupted.  This  can  be  caused  by  a  blood  clot  that  
impairs  blood  flow  in  a  coronary  artery.  The  loss  of  blood  supply,  referred  
to  as  ischemia,  impairs  delivery  of  oxygen  and  nutrients  to  the  region  of  
the  heart  supplied  by  the  affected  artery.  In  addition,  the  removal  of  waste  
products  is  impaired.  If  this  is  sustained  for  long  enough,  cell  death  can  
result  and  a  region  of  dead  tissue,  or  infarct,  can  form21.  Cardiomyocytes,  
i.e.  the  muscle  cells  of  the  heart,  comprise  more  than  90%  of  the  heart‟s  
mass  and  their  death  impairs  contractile  function.  The  size  of  the  infarct,  
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which  is  related  to  the  extent  of  cardiomyocyte  death,  influences  the  
severity  of  contractile  dysfunction. 
Multiple  modes  of  cell  death  occur  in  the  context  of  myocardial  
infarction.  For  a  long  time,  necrosis  (the  uncontrolled  death  of  cells,  which  
can  occur  in  response  to  trauma)  was  considered  to  be  solely  responsible.  
However,  studies  later  identified  a  role  for  apoptosis  in  cell  death  during  
myocardial  infarction20.  Unlike  necrosis,  apoptosis  (or  programmed  cell  
death)  is  a  tightly-regulated,  energy-dependent  process.  Intracellular  signaling  
is  crucial  in  regulating  the  initiation  of  apoptosis22. 
 
2.1  Hypoxia  initiates  JAK/STAT  signaling 
The  impaired  supply  of  oxygen  to  the  ischemic  region  during  
myocardial  infarction  results  in  hypoxia,  i.e.  an  oxygen  deficit.  This  leads  to  
impaired  energy  production  -  a  serious  threat  to  cardiomyocytes,  which  
have  a  high  metabolic  demand.  When  cardiomyocytes  are  exposed  to  
hypoxia,  a  stress-response  is  elicited,  a  number  of  cytokines  are  produced  
including  interleukin-6  (IL-6)23.  When  IL-6  binds  to  its  receptor  (IL-6R)  on  
neighboring  cardiomyocytes,  glycoprotein  130  (gp130)  molecules  can  be  
recruited  (see  Figure  1).  The  association  of  two  gp130  molecules  is  the  
final  step  in  the  formation  of  the  cytokine  receptor  complex.  Each  gp130  
molecule  is  constitutively  associated  with  a  JAK  protein  such  that  
recruitment  of  two  gp130  molecules  brings  two  JAK  proteins  into  close  
proximity.  JAK  proteins  are  intracellular  kinases,  which  phosphorylate  
tyrosine  residues  in  proteins.  Four  mammalian  JAK  proteins  have  been  
identified,  namely  JAK1,  2,  3  and  Tyk2.  Upon  formation  of  the  complete  
cytokine  receptor  complex,  JAK  proteins  phosphorylate  and  activate    
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Figure  1:  The  initiation  of  JAK/STAT  signaling  in  response  to  hypoxia.  
IL-6  binding  to  its  receptor  recruits  two  gp130  molecules  with  their  associated  
JAK  proteins.  JAK  proteins  phosphorylate  themselves  and  the  gp130  molecules,  
creating  docking  sites  for  STAT  proteins  to  bind.  Once  they  are  bound,  STAT  
proteins  become  phosphorylated  before  translocating  into  the  nucleus  and  
regulating  expression  of  cardioprotective  factors.  Abbreviations  gp130:  
glycoprotein  130,  IL-6:  interleukin-6,  IL-6R:  interleukin-6  receptor,  JAK:  Janus  
kinase,  STAT3:  signal  transducer  and  activator  of  transcription.  
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themselves  as  well  as  intracellular  tyrosine  residues  on  gp130,  creating  
docking  sites  for  STAT  proteins15.  STAT  proteins  are  cytosolic  proteins,  
which  are  known  for  their  role  as  transcription  factors,  which  regulate  
transcription  of  a  specific  set  of  genes.  Seven  STAT  proteins  have  been  
identified  in  mammals,  namely  STAT1,  2,  3,  4,  5a,  5b  and  6.  In  the  case  of  
JAK/STAT  signaling  induced  by  IL-6,  it  is  STAT3  that  binds  to  the  cytokine  
receptor  complex.  Once  bound,  STAT3  proteins  are  phosphorylated  by  
activated  JAK  proteins  and  homodimerize.  They  then  dissociate  from  the  
cell  membrane  and  translocate  to  the  nucleus  in  order  to  regulate  the  
expression  of  genes  that  code  for  cardioprotective  factors.  For  example,  
STAT3  activation  can  lead  to  increased  production  of  vascular  endothelial  
growth  factor  (VEGF),  a  cytokine  that  initiates  angiogenesis17.  Angiogenesis  
can  oppose  hypoxia  by  providing  collateral  blood  (and  oxygen)  supply  to  
the  ischemic  region.  Thus,  cardiomyocytes  can  counteract  hypoxia  and  act  
to  restore  homeostasis  by  Il-6  release,  JAK/STAT  signaling  and  initiating  
angiogenesis.   
In  addition  to  opposing  the  threat  of  hypoxia  by  promoting  
angiogenesis,  STAT3  is  also  associated  with  upregulation  of  anti-apoptotic  
genes  such  as  Bcl-2  and  Pim-1,  as  well  as  downregulation  of  pro-apoptotic  
genes  such  as  Bax24.  In  this  way,  JAK/STAT  signaling  functions  to  promote  
survival.  In  contrast,  STAT1  has  been  linked  to  pro-apoptotic  effects.  This  
review  specifically  focuses  on  the  role  of  JAK/STAT  in  pro-survival  signaling,  
which  is  mediated  by  activation  of  STAT3.  
The  translocation  of  STAT3  to  the  nucleus  and  its  role  as  a  
transcription  factor  are  well-established.  It  was  assumed  that  the  sole  
function  of  STAT3  was  regulating  gene  expression,  however,  an  additional  
role  was  recently  discovered.  The  identification  of  STAT3  in  cardiomyocyte  
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mitochondria  in  2009  led  to  the  suggestion  of  its  involvement  in  regulating  
respiration25.  STAT3  was  subsequently  shown  to  translocate  to  the  
mitochondrion  where  it  is  thought  to  regulate  the  activity  of  complexes  I  
and  II  of  the  electron  transport  chain26.  In  addition,  it  may  inhibit  opening  
of  the  mitochondrial  permeability  transition  pore  (mPTP),  a  non-selective  
channel  of  the  inner  mitochondrial  membrane27,  and  is  proposed  to  act  as  
an  electron  scavenger  that  reduces  levels  of  reactive  oxygen  species  
(ROS)28.  The  consequences  of  these  effects will  be  elaborated  upon  at  a  
later  stage  since  they  act  in  concert  with  the  effects  of  signaling  via  
PI3K/Akt,  another  endogenous  survival  mechanism  that  exists  in  the  heart. 
 
2.2  Ischemia  initiates  PI3K/Akt  signaling 
In  addition  to  inducing  hypoxia  and  the  associated  IL-6  secretion,  
ischemia  also  leads  to  the  release  of  adenosine  by  heart  cells18.  Binding  of  
adenosine  to  its  receptor  on  surrounding  cells  is  associated  with  activation  
of  the  PI3K/Akt  signaling  pathway19.  PI3K  is  a  kinase  that  phosphorylates  
membrane-embedded  phosphatidylinositol  4,5-bisphosphate  (PIP2)  to  form  
phosphatidylinositol  3,4,5-trisphosphate  (PIP3).  PIP3  is  responsible  for  
recruiting  Akt  and  3-phosphoinositide-dependent  protein  kinase  (PDK)  to  
the  membrane,  bringing  them  into  close  proximity  (see  Figure  2).  PDK,  a  
constitutively  active  kinase,  phosphorylates  and  activates  Akt.  Once  Akt  is  
phosphorylated,  it  leaves  the  cell  membrane  and  prevents  apoptosis  by 
phosphorylating  a  wide  range  of  proteins.  Like  STAT3,  Akt  can  promote  
cell  survival  by  effects  that  act  at  the  mitochondrion  as  well  as  effects  that  
act  at  the  nucleus29.  However,  this  review  focuses  primarily  on  its  
pro-survival  effects  at  the  mitochondrion.   
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Figure  2:  The  initiation  of  PI3K/Akt  signaling  in  response  to  ischemia.  
Binding  of  adenosine  to  its  receptor  activates  PI3K/Akt  signaling.  PI3K  
phosphorylates  PIP2  to  form  PIP3,  which  recruits  Akt  and  PDK  to  the  membrane,  
bringing  them  into  close  proximity.  PDK  phosphorylates  and  activates  Akt,  which  
prevents  apoptosis  by  phosphorylating  proteins  such  as  Bad,  eNOS,  Pim-1,  GSK-3  
and  FOXO.  Abbreviations  eNOS:  endothelial  nitric  oxide  synthase,  FOXO:  
forkhead  box  O,  GSK-3ß:  glycogen  synthase  kinase-3ß,  PDK:  3-phosphoinositide-
dependent  protein kinase,  PI3K:  phosphatidylinositol  3-kinase,  PIP2: 
phosphatidylinositol  4,5-bisphosphate,  PIP3:  phosphatidylinositol  3,4,5-trisphosphate.  
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Activated  Akt  can  prevent  apoptosis  by  phosphorylating  proteins  such  as  
Bad,  a  pro-apoptotic  protein  that  is  inactivated  by  phosphorylation30.  Pim-1  
can  also  be  activated  by  Akt,  enabling  it  to  carry  out  anti-apoptotic  actions  
of  its  own.  These  include  phosphorylating  and  inactivating  pro-apoptotic  
proteins  and  indirectly  causing  increases  in  anti-apoptotic  proteins31.  Akt  can  
also  influence  gene  expression  through  phosphorylation  of  transcription 
factors  such  as  the  forkhead  box  O  (FOXO)  proteins32.  Phosphorylation  of  
FOXO  leads  to  its  export  from  the  nucleus,  where  it  induces  the  
expression  of  pro-apoptotic  genes33. 
Thus,  both  the  PI3K/Akt  and  JAK/STAT  pathways  can  act  to  inhibit  
apoptosis  via  actions  at  the  nucleus  as  well  as  actions  at  the  mitochondria.  
Interestingly,  the  JAK/STAT  and  PI3K/Akt  signaling  pathways  can  act  in  
concert.  
 
2.3  JAK/STAT  and  PI3K/Akt  cooperate  to  prevent  apoptosis 
Although  both  JAK/STAT  and  PI3K/Akt  signaling  can  influence  
transcription,  the  following  section  will  focus  on  their  role  in  the  
mitochondria.  Here  the  complementary  nature  of  their  effects  are  
eloquently  displayed. 
A  substantial  body  of  evidence  exists  for  cross-regulation  between  
the  PI3K/Akt  and  JAK/STAT  signaling  pathways.  This  is  demonstrated  in  
settings  where  PI3K  is  able  to  phosphorylate  STAT334  and  JAK2  is  able  to  
phosphorylate  Akt  after  binding  to  PI3K35.  Numerous  examples  exist  where  
STAT3  activation  is  reported  to  be  dependent  on  PI3K/Akt  signaling  or  vice  
versa,  and  a  number  of  cardioprotective  stimuli  activate  both  PI3K/Akt  and  
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JAK/STAT  signaling36.  In  addition,  cases  have  been  reported  where  inhibition  
of  PI3K/Akt  signaling  reduced  STAT3  phosphorylation  in  pulmonary  artery  
endothelial  cells37  and  inhibiting  JAK/STAT  signaling  reduced  Akt  
phosphorylation  in  cardiomyocytes38.  Thus,  a  variety  of  facts  support  the  
notion  that  PI3K/Akt  and  JAK/STAT  signaling  are  inter-regulated39.   
In  addition  to  their  inter-regulation,  the  notion  of  cooperation  
between  these  pathways  is  supported  by  their  proposed  convergence  at  the  
mitochondrion40,41.  The  mitochondrion  is  a  double-membraned  organelle,  
which  is  responsible  for  producing  adenosine  triphosphate  (ATP)  from  
NADH  and  FADH2.  In  addition  to  this  crucial  role,  mitochondria  also  have  
an  important  function  in  apoptosis.  The  intrinsic  pathway  of  apoptosis  is  
mediated  by  the  mitochondria  and  the  Bcl-2  family  of  apoptosis  regulators42.  
This  family  of  proteins  can  be  divided  into  two  groups:  those  that  are  
anti-apoptotic  (such  as  Bcl-xL,  Bcl-2  and  Mcl-1)  and  those  that  are  
pro-apoptotic  (such  as  Bad,  Bax  and  Bak).  These  two  groups  of  proteins  
are  thought  to  antagonize  one  another  until  this  dynamic  balance  is  altered  
in  favor  of  apoptosis.  When  this  occurs,  Bax  and  Bak  oligomerize,  forming  
pores  that  induce  mitochondrial  membrane  permeabilization43.  This  leads  to  
loss  of  membrane  integrity,  cytochrome  c  release,  apoptosome  formation  
and  the  initiation  of  apoptosis42.  Another  proposed  means  by  which  
membrane  integrity  can  be  lost  (causing  release  of  pro-death  factors  and  
apoptosis  initiation)  is  mPTP  opening44. 
The  initiation  of  apoptosis  can  be  prevented  by  PI3K/Akt  signaling  in  
several  ways  (see  Figure  3).  Phosphorylation  and  inhibition  of  the  
pro-apoptotic  protein  Bad  by  activated  Akt  causes  it  to  dissociate  from  the  
anti-apoptotic  protein  Bcl-xL
30.  This  increases  the  availability  of  Bcl-xL  
proteins,  which  are  freed  to  bind  and  inhibit  other  pro-apoptotic  proteins.    
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Figure  3:  The  role  of  the  PI3K/Akt  and  JAK/STAT  signaling  pathways  in  
preventing  apoptosis.  PI3K/Akt  signaling  leads  to  the  prevention  of  Bax/Bak  
oligomerization.  It  also  prevents  opening  of  the  mitochondrial  permeability  
transition  pore  by  inhibiting  GSK-3β.  JAK/STAT  signaling  and  translocation  of  
STAT3  to  the  mitochondrion  is  proposed  to  reduce  ROS  production  by  regulating  
the  activity  of  complexes  I  and  II  of  the  electron  transport  chain.  Attenuated  
ROS  production  and  STAT3’s  proposed  direct  effect  on  the  mPTP  lead  to  the  
prevention  of  mPTP  opening.  Thus,  PI3K/Akt  and  JAK/STAT  signaling  cooperate  to  
prevent  cytochrome  c  release  and  apoptosis  initiation.  Abbreviations  cyt c:  
cytochrome  c,  eNOS:  endothelial  nitric  oxide  synthase,  ETC:  electron  transport  
chain,  GSK-3β:  glycogen  synthase  kinase-3β,  mPTP:  mitochondrial  permeability  
transition  pore,  NO:  nitric  oxide,  PI3K:  phosphotidylinositol  3-kinase,  ROS:  reactive  
oxygen  species,  STAT:  signal  transducer  and  activator  of  transcription.  
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Phosphorylation  of  the  pro-apoptotic  protein  Bax  by  activated  Akt  causes  a  
change  in  its  conformation,  preventing  its  translocation  to  the   
mitochondrion.  Bax  phosphorylation  may  also  act  to  promote  its  association  
with  anti-apoptotic  proteins.  Activated  Akt  also  causes  phosphorylation  and  
inhibition  of  glycogen  synthase  kinase-3β  (GSK-3β),  which  leads  to  inhibition  
of  mPTP  opening  and  maintenance  of  the  anti-apoptotic  protein  Mcl-145,46.   
Activated  Akt  is  also  associated  with  phosphorylation  and  activation  
of  endothelial  nitric  oxide  synthase  (eNOS),  thereby  restoring  nitric  oxide  
production,  which  is  thought  to  prevent  mPTP  opening47.  Therefore,  
PI3K/Akt  signaling  leads  to  several  effects  that  oppose  apoptosis  and  
promote  survival. 
Similarly,  JAK/STAT  signaling  also  acts  to  prevent  apoptosis.  The  
translocation  of  STAT3  to  the  mitochondrion  and  its  proposed  regulation  
of  complexes  I  and  II  are  thought  to  be  important  in  limiting  electron  leak  
from  the  electron  transport  chain  and  reducing  superoxide  production40.  
This,  along  with  its  suggested  role  as  a  ROS  scavenger  and  its  proposed  
direct  effects  on  the  mPTP27  are  thought  to  prevent  mPTP  opening.  
Therefore,  signaling  via  PI3K/Akt  and  JAK/STAT  can  cooperate  to  prevent  
apoptosis  by  mutual  regulation  and  by  their  converging  effects  at  the  
mitochondria. 
 
3.  The  penalty  of  reperfusion 
Although  PI3K/Akt  and  JAK/STAT  signaling  may  assist  cells  in  
avoiding  apoptosis,  their  capacity  is  limited.  Restoration  of  blood  flow  
(referred  to  as  reperfusion)  must  eventually  be  initiated  in  order  for  cells  
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to  survive48.  Reperfusion  therapy  is  the  primary  means  of  treating  
myocardial  infarction  and  it  can  be  achieved  in  two  ways.  The  first  method  
is  thrombolysis,  which  involves  administering  drugs  to  dissolve  the  offending  
blood  clot(s).  Another  method  is  percutaneous  coronary  intervention,  
whereby  a  balloon-tipped  catheter  is  inserted  into  the  blocked  artery  and  
inflated  to  restore  blood  flow  mechanically.  The  sooner  reperfusion  is  
initiated,  the  larger  the  region  of  myocardium  that  can  be  salvaged.  
However,  paradoxically,  the  sudden  restoration  of  blood  flow  can  itself  
cause  cell  death,  known  as  lethal  reperfusion  injury49.  The  following  section  
will  give  a  brief  overview  of  the  underlying  pathology  of  lethal  reperfusion  
injury. 
The  sudden  restoration  of  blood  flow  at  the  onset  of  reperfusion  
induces  a  number  of  rapid  changes  (see  Figure  4).  These  changes  cause  a  
series  of  perturbations  at  the  level  of  the  mitochondrion,  which  act  in  
concert  to  cause  cell  death48.  Firstly,  the  sudden  restoration  of  oxygen  and  
nutrient  supply  leads  to  a  dramatic  increase  in  ROS  production  by  the  
electron  transport  chain.  Excessive  ROS  damage  the  sarcolemma  and  impair  
function  of  the  sarcoplasmic  reticulum,  causing  calcium  overload.  Secondly,  
the  removal  of  lactic  acid,  which  accumulated  during  ischemia,  and  the  
activation  of  the  sodium-hydrogen  exchanger  lead  to  the  rapid  restoration  
of  normal  pH.  These  changes  act  in  concert  to  mediate  opening  of  the  
mPTP50.   
During  myocardial  ischemia,  the  mPTP  remains  closed,  but  the  
sudden  changes  that  occur  at  the  onset  of  reperfusion  lead  to  its  opening.  
As  aforementioned,  opening  of  the  mPTP  leads  to  the  initiation  of  
apoptosis  by  cytochrome  c  release  and  apoptosome  formation49.  mPTP  
opening  is  thought  to  be  a  major  determinant  of  lethal  reperfusion  injury41.  
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Figure 4:  The  underlying  pathology  of  lethal  reperfusion  injury.  
Restoration  of  oxygen  and  nutrient  supply  increases  ROS  production  by  the  
electron  transport  chain.  Simultaneously,  calcium  levels  increase  and  pH  is  rapidly  
restored.  These  changes  cause  opening  of  the  mPTP,  which  is  linked  to  
cytochrome  c  release.  Oligomerization  of  Bak  or  Bax  is  another  stimulus  thought  
to  favor  cytochrome  c  release.  Cytochrome  c  release  causes  apoptosome  
formation  and  the  initiation  of  apoptosis.  Abbreviations  cyt  c:  cytochrome  c,  
ETC:  electron  transport  chain,  mPTP:  mitochondrial  permeability  transition  pore,  
ROS:  reactive  oxygen  species.  
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4.  The  promise  of  postconditioning 
Postconditioning  is  a  therapy  that  aims  to  reduce  lethal  reperfusion  
injury.  It  involves  the  induction  of  brief,  alternating  periods  of  ischemia  and  
reflow  at  the  onset  of  reperfusion.  In  this  way,  the  restoration  of  blood  
flow  is  interrupted  by  intermittent  periods  of  ischemia.  In  a  clinical  setting,  
this  procedure  would  require  the  insertion  of  a  balloon-tipped  catheter  as  
with  percutaneous  coronary  intervention,  and  a  series  of  alternating  
inflations  and  deflations  of  the  balloon. 
Since  it  was  first  applied  in  dogs  in  2003,  studies  have  demonstrated  
its  effectiveness  using  various  animal  models51.  The  lengths  of  the  alternating  
periods  of  ischemia  and  reperfusion  typically  vary  between  1  and  3  minutes,  
depending  on  the  species.  The  use  of  longer  periods  and  the  application  of  
treatment  later  than  the  first  few  minutes  of  reperfusion  proved  ineffective.  
A  reduction  in  infarct  size  was  commonly  selected  as  the  primary  end  
point  and  a  clear  role  for  postconditioning  in  reducing  infarct  size  was  
soon  established.  Small-scale  clinical  trials  also  found  postconditioning  to  be  
an  effective  treatment  for  myocardial  infarction52,53.   
However,  this  experimental  procedure  is  limited  in  terms  of  
practicality  and  applicability.  This  procedure  must  be  carried  out  within  the  
first  few  minutes  of  reperfusion  to  be  effective,  which  is  challenging  since  
most  myocardial  infarction  patients  do  not  have  quick  access  to  a  facility  
for  performing  percutaneous  coronary  intervention.  In  addition,  its  benefit  is  
impaired  by  the  presence  of  comorbidities  such  as  hyperglycemia,  
hypercholesterolemia  and  hypertension,  all  of  which  are  common  in  patients  
undergoing  treatment  for  myocardial  infarction. 
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These  limitations  led  researchers  to  investigate  the  underlying  
molecular  mechanisms  of  postconditioning-induced  cardioprotection,  with  the  
aim  of  pharmacologically  activating  them.  Thus,  „pharmacological  
postconditioning‟  seeks  to  induce  cardioprotection  using  a  pharmacological  
agent  that  mimics  the  effects  of  traditional,  mechanical  postconditioning.  This  
is  a  more  accessible  alternative  with  the  potential  to  produce  comparable  
results. 
Postconditioning  acts  by  initiating  endogenous  survival  mechanisms  in  
the  heart.  These  mechanisms  are  referred  to  as  the  „reperfusion  injury  
salvage  kinase  (RISK)  pathway‟  and  the  „survivor  activating  factor  
enhancement  pathway  (SAFE).  The  RISK  pathway  encompasses  signaling  via  
the  mitogen-activated  protein  kinase/ERK  kinase  (MEK)/extracellular  
signal-regulated  kinase  (ERK)  1/2  signaling  pathway,  i.e.  the  MAPK  pathway,  
as  well  as  the  PI3K/Akt  pathway54.  The  SAFE  pathway  involves  the  cytokine  
tumor  necrosis  factor-α  (TNF-α)  and  STAT355,56.  Numerous  studies  have  
confirmed  that  the  RISK  and  SAFE  pathways  confer cardioprotection  when  
activated  during  reperfusion22,57. 
Despite  a  number  of  potential  targets  being  investigated,  no  
pharmacological  postconditioning  agent  has  gained  clinical  acceptance  for  the  
routine  treatment  of  myocardial  infarction  as  yet.  Therefore,  a  need  
remains  for  a  treatment  able  to  mimic  the  effects  of  postconditioning,  
which  can  be  implemented  as  a  standardized  treatment  for  myocardial  
infarction.  Research  within  our  group  has  identified  a  potential  role  for  
benfotiamine  in  pharmacological  postconditioning.  In  the  following  section,  
the  discovery  and  characteristics  of  benfotiamine  will  be  described.  
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5.  The  therapeutic  potential  of  benfotiamine 
Benfotiamine  is  one  of  a  number  of  thiamine  (vitamin  B1)  derivatives  
(Figure  5)  that  have  been  investigated  for  therapeutic  use.  After  allithiamine,  
a  naturally-occurring  thiamine  derivative,  was  discovered  in  Japan  in  195158,  
researchers  synthesized  a  group  of  additional  thiamine  derivatives  with  
improved  bioavailability.  They  proceeded  to  assess  the  value  of  these  
compounds  in  treating  various  diseases59. 
Figure  5:  The  chemical  structure  of  thiamine  and  benfotiamine.  
Benfotiamine  is  a  benzoylated  derivative  of  the  phosphorylated  form  of  thiamine.  
 
Benfotiamine,  or  S-benzoylthiamine  O-monophosphate,  has  primarily 
been  investigated  as  a  treatment  for  diabetes-related  nervous  and  
cardiovascular  disorders.  This  section  focuses  specifically  on  benfotiamine‟s  
beneficial  effects  on  the  heart.  Firstly,  the  proposed  mechanisms  in  diabetic  
cardiomyopathy  are  described  and  studies  exploring  benfotiamine  as  a  
treatment  are  discussed.  Secondly,  benfotiamine‟s  potential  in  treating  
myocardial  infarction  is  examined.  Thirdly,  the  effects  of  benfotiamine  on  
cardiac  progenitor  cells  are  described.  Next,  the  therapeutic  capacity  of  the  
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pentose  phosphate  pathway  is  explored.  Finally,  a  potential  role  for  
benfotiamine  in  pharmacological  postconditioning  is  described. 
 
 
5.1  Treating  diabetic  cardiomyopathy 
Diabetes  is  associated  with  various  metabolic  alterations,  including  
hyperglycemia.  Hyperglycemia,  in  turn,  leads  to  a  range  of  perturbations.  In  
the  heart,  these  perturbations  can  lead  to  systolic  and  diastolic  dysfunction.  
When  this  occurs  independently  of  atherosclerosis  and  hypertension,  it  is  
termed  diabetic  cardiomyopathy. 
Recently,  a  unifying  hypothesis  was  proposed  describing  mitochondrial  
superoxide  as  the  cause  of  multiple  hyperglycemia-induced  perturbations60–62.  
Based  on  this  hypothesis,  a  comprehensive  explanation  for  the  
hyperglycemia-induced  perturbations  in  diabetic  cardiomyopathy  was  
described63.  In  addition,  benfotiamine  was  proposed  as  a  comprehensive  
treatment  that  could  counteract  these  perturbations64.  These  propositions  
will  now  be  elaborated  upon. 
Hyperglycemia,  or  an  elevated  glucose  concentration,  is  associated  
with  increased  mitochondrial  superoxide  (O2-)  production  (Figure  6)65.  This  
occurs  as  result  of  an  overproduction  of  electron  donors  (NADH  and  
FADH2)  by  the  citric  acid  cycle.  Excessive  mitochondrial  superoxide  is  
thought  to  cause  DNA  damage  and  activation  of  poly(ADP-ribose)  
polymerase  (PARP),  an  enzyme  that  is  responsible  for  DNA  repair62.  
However,  PARP  activation  can  inhibit  glyceraldehyde  phosphate  
dehydrogenase  (GAPDH),  a  key  enzyme  in  glycolysis  (the  central  pathway  in  
glucose  metabolism)66.  This  causes  a  build-up  of  glycolytic  metabolites  
upstream  of  GAPDH,  which  diverge  into  non-oxidative  glucose  pathways62.  
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Figure  6:  Hyperglycemia-induced  perturbations  involved  in  diabetic  
cardiomyopathy.  Under  hyperglycemic  conditions,  mitochondrial  superoxide  
overproduction  leads  to  GAPDH  inhibition.  This  leads  to  a  build-up  of  upstream  
metabolites  and  excessive  flux  through  non-oxidative  glucose  pathways  (indicated  
by  blue  boxes).  This  leads  to  oxidative  stress,  systolic  dysfunction  and  diastolic  
dysfunction.  Abbreviations  AGE:  advanced  glycation  endproducts,  DAG:  
diacylglycerol,  GAPDH:  glyceraldehyde  phosphate  dehydrogenase,  HP:  hexosamine  
biosynthetic,  O2
-:  superoxide,  PARP:  poly(ADP-ribose)  polymerase,  PKC:  protein  
kinase  C.  
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More  specifically,  flux  through  the  polyol  pathway  increases,  there  is  
an  increase  in  advanced  glycation  end-product  (AGE)  formation,  activation  of  
protein  kinase  C  (PKC)  isoforms  occurs  and  flux  through  the  hexosamine  
biosynthetic  pathway  (HBP)  is  increased67.  Excessive  flux  through  these  
pathways  in  the  heart,  such  as  is  thought  to  occur  in  hyperglycemia,can  
have  detrimental  effects63. 
Firstly,  increased  flux  through  the  HBP  causes  impaired  relaxation  of  
the  heart68.  Secondly,  excessive  AGE  formation  is  associated  with  reduced  
contractility,  increased  ventricular  stiffness  and  impaired  ventricular  filling69,70.  
Thirdly,  excessive  flux  through  the  polyol  pathway  exacerbates  oxidative  
stress,  promotes  cardiomyocyte  apoptosis  and  increases  ventricular  stiffness71.  
Finally,  excessive  activation  of  PKC  isoforms  leads  to  cardiac  hypertrophy,  
impaired  relaxation  and  increased  ventricular  stiffness72.  Thus,  
hyperglycemia-induced  perturbations  are  associated  with  oxidative  stress,  
systolic  dysfunction  and  diastolic  dysfunction  of  the  heart63,  which  are  
characteristic  of  the  diabetic cardiomyopathy60.    
In  contrast,  benfotiamine  administration  increases  flux  through  the  
pentose  phosphate  pathway  (Figure  7)73,74.  This  is  thought  to  shunt  glycolytic  
metabolites  away  from  these  non-oxidative  glucose  pathways,  attenuating  
downstream  negative  effects  (Figure  6).  Flux  though  the  pentose  phosphate  
pathway  increases  production  of  ribose  5-phosphate,  which  is  required  for  
DNA  repair,  and  NADPH,  which  regulates  redox  balance.  The  therapeutic  
potential  of  the  pentose  phosphate  pathway  will  be  elaborated  upon  at  a  
later  stage.  
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Figure  7:  The  role  of  benfotiamine  in  glucose  metabolism.  Thiamine  is  a  
cofactor  for  TK,  PDH  and  α-KGDH.  Benfotiamine  administration  increases  TK  and  
G6PD  activity,  thereby  increasing  flux  of  glycolytic  metabolites  into  the  pentose  
phosphate  pathway.  This  increases  the  production  of  ribose  5-phosphate  and  
NADPH,  which  regulates  redox  balance.  Abbreviations  1,3-bis-PGly:  
1,3-bisphosphoglycerate,  3-PGra:  glyceraldehyde  3-P,  6-PGcl:  6-P  gluconolactone,  
6-PGlt:  6-P  gluconate,  α-KGDH: α-ketoglutarate  dehydrogenase.  Ery4-P:  erythrose  
4-P,  Fru6-P:  fructose  6-P,  G6PD:  glucose  6-phosphate  dehydrogenase,  Glu6-P:  
glucose  6-P,  Gra3-P:  glyceraldehyde  3-P,  PDH:  pyruvate  dehydrogenase,  Rib5-P:  
ribose  5-P,  Rul5-P:  ribulose  5-P,  Seh7-P:  sedoheptulose  7-P,  TK:  transketolase,  
Xlu5-P:  xylulose  5-P.  
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Benfotiamine‟s  ability  to  treat  diabetic  cardiomyopathy  was  tested  in  
three  studies.  The  first  study  was  carried  out  to  investigate  the  roles  of  
AGEs,  the  AGE  receptor  (RAGE),  and  methylglyoxal  (the  key  intermediate  
in  AGE  formation)  in  diabetic  cardiomyopathy.  Six  weeks  of  benfotiamine  
treatment  in  mice  attenuated diabetes-induced  increases  in  collagen,  
methylglyoxal,  RAGE  and  methylglyoxal-derived  AGE  formation  in  the  
heart75. 
The  second  study  evaluated  the  effects  of  benfotiamine  treatment  on  
diabetes-induced  contractile  dysfunction.  Control  and  diabetic  mice  received  
benfotiamine  treatment  for  two  weeks  prior  to  cardiomyocyte  isolation.  
Benfotiamine  treatment  counteracted  diabetes-induced  contractile  dysfunction  
and  reduced  oxidative  stress,  as  reflected  by  the  reduced  glutathione-to-
glutathione  disulfide  ratio  (GSH:GSSG)76.  
A  third  study  was  designed  to  investigate  the  efficacy  of  long-term  
benfotiamine  supplementation  (8  or  16  weeks)  in  preventing  diabetic  
cardiomyopathy  in  mice.  Hearts  of  untreated  diabetic  mice  showed  reduced  
activity  of  transketolase  (TK),  glucose  6-phosphate  dehydrogenase  (G6PD)  
and  GAPDH.  Furthermore,  ROS  production  and  cardiomyocyte  apoptosis  
were  elevated.  The  progression  of  diabetic  cardiomyopathy  was  associated  
with  reduced  phosphorylation  of  STAT3,  Akt,  eNOS,  FOXO  and  Bad,  in  
addition  to  reduced  levels  of  Pim-1  and  Bcl-2.  Benfotiamine  prevented  all  of  
these  alterations.  Inhibition  of  Akt  ablated  benfotiamine‟s  anti-apoptotic  
effects,  but  STAT3  inhibition  had  no  effect.  This  suggests that  benfotiamine‟s  
pro-survival  effects  are  mediated  by  Akt.  The  investigators  concluded  that  
benfotiamine  warrants  consideration  for  clinical  application77. 
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These  studies  indicate  that  benfotiamine  supplementation  may  have  
therapeutic  potential  as  a  treatment  for  diabetic  cardiomyopathy.  In  addition,  
a  potential  role  for  benfotiamine  in  preventing  apoptosis  was  identified.  This  
pro-survival  role  has  also  been  investigated  in  the  context  of  myocardial  
infarction. 
 
5.2  Treating  myocardial  infarction 
Hyperglycemia  is  common  during  myocardial  infarction.  Chronic  
hyperglycemia  is  characteristic  of  diabetes  mellitus,  a  disease  with  a  high  
global  prevalence,  especially  amongst  myocardial  infarction  patients.  In  
addition,  acute  hyperglycemia  occurs  during  myocardial  infarction  in  
non-diabetic  patients,  as  result  of  sympathetic  nervous  system  activation  in  
response  to  stress.  The  presence  of  hyperglycemia  during  myocardial  
infarction  is  associated  with  increased  mortality78.  Two  studies  have  
investigated  the  role  of  benfotiamine  in  treating  myocardial  infarction,  with  
and  without  hyperglycemia. 
The  first  study  addressed  the  effects  of  chronic  benfotiamine  
supplementation  on  the  consequences  of  ischemia  ±  chronic  hyperglycemia.  
In  addition,  the  activation  of  pro-survival  signaling  was  assessed13.  In  
non-diabetic  mice,  ischemia  activated  an  endogenous  survival  mechanism  
involving  activation  of  the  pentose  phosphate  pathway  enzymes  TK  and  
G6PD.  This  was  associated  with  vascular  endothelial  growth  factor  receptor  
2  (VEGFR2)/Akt  signaling  and  increased  levels  of  pAkt,  Pim-1,  pBad  and  
Bcl-2.  This  survival  mechanism  was  impaired  in  diabetic  mice  but  could  be  
restored  by  benfotiamine  supplementation,  resulting  in  improved  survival,  
reduced  oxidative  stress,  enhanced  functional  recovery,  improved  
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angiogenesis,  attenuated  mitochondrial  dysfunction  and  decreased  apoptosis13.  
These  findings  were  complemented  by  experiments  in  isolated  
cardiomyocytes,  where  benfotiamine  treatment  activated  and  preserved  
VEGFR2/Akt/Pim-1  signaling  under  hypoxic  and  hyperglycemic  conditions.   
Therefore,  ischemia  or  long-term  benfotiamine  supplementation  can  
activate  a  survival  mechanism  in  the  heart  involving  activation  of  enzymes  
of  the  pentose  phosphate  pathway  and  VEGFR2/Akt/Pim-1  signaling.   
The  second  study,  performed  by  our  group,  addressed  the  effects  of  
acute  benfotiamine  administration  on  the  consequences  of  
ischemia-reperfusion  ±  acute  hyperglycemia.  In  addition,  the  effects  of  flux  
through  the  non-oxidative  glucose  pathways  was  assessed12.  Isolated  rats  
hearts  that  underwent  retrograde  perfusion  under  hyperglycemic  conditions  
displayed  increased  flux  through  the  polyol  and  AGE  pathways,  which  was  
associated  with  exacerbated  oxidative  stress  and  increased  cell  death.  Acute  
benfotiamine  administration  at  the  onset  of  reperfusion  counteracted  these  
alterations.  Hearts  were  exposed  to  ischemia  and  reperfusion  under  
hyperglycemic  conditions,  resulting  in  reduced  TK  activity,  greater  PARP  
activation,  reduced  GAPDH,  elevated  oxidative  stress  and  increased  
apoptosis.  Acute  benfotiamine  administration  once  again  counteracted  these  
alterations.  Interestingly,  benfotiamine  administration  also  improved  functional  
recovery  and  reduced  infarct  size  after  ischemia-reperfusion,  under  both  
hypoglycemic  and  normoglycemic  conditions. 
To  summarize,  acute  benfotiamine  administration  was  beneficial  in  
restoring  normal  glucose  metabolism  and  attenuating  hyperglycemia-induced  
perturbations,  thereby  preventing  oxidative  stress.  In  addition,  benfotiamine  
administration  reduced  infarct  size  and  improved  functional  recovery  after  
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ischemia-reperfusion,  under  both  normoglycemic  conditions  and  
hyperglycemic  conditions. 
Thus,  treatment  with  benfotiamine,  chronically  or  acutely,  can  prevent  
the  worsening  of  ischemia-induced  dysfunction  by  the  presence  of  
hyperglycemia.  In  addition,  benfotiamine  treatment  is  associated  with  the  
activation  of  an  endogenous  survival  mechanism,  reduced  infarct  size  and  
improved  functional  recovery  in  response  to  ischemia,  independent  of  
hyperglycemia-related  effects.  These  effects  warrant  further  investigation. 
 
 
5.3  Restoring  cardiogenesis 
As  previously  discussed,  cell  death  resulting  from  myocardial  
infarction  impairs  contractile  function.  The  remaining  cells  are  faced  with  a  
significantly  increased  workload,  which  threatens  their  survival.  A  limited  
number  of  cardiac  progenitor  (or  stem)  cells  reside  in  the  heart,  which  are  
able  to  differentiate  into  cardiomyocytes,  smooth  muscle  cells,  and  vascular  
endothelial  cells.  A  clinical  trial  recently  demonstrated  the  ability  of  infused  
cardiac  progenitor  cells  to  increase  viable  heart  tissue  and  improve  
restoration  of  function  after  myocardial  infarction79.  However,  this  crucial  
cardiac  repair  mechanism  is  compromised  in  diabetes.   
A  recent  study  found  reduced  abundance  and  proliferation  of  cardiac  
progenitor  cells  in  diabetic  mice80.  Cardiac  progenitor  cells  isolated  from  
these  mice  displayed  impaired  TK  and  G6PD  activity,  higher  levels  of  
superoxide  and  AGEs,  and  inhibited  Akt/Pim-1/Bcl-2  signaling.  Human  and  
mouse  cardiac  progenitor  cells  cultured  in  high  glucose  showed  similar  
perturbations,  which  were  associated  with  increased  apoptosis.  Benfotiamine  
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administration  restored  pentose  phosphate  pathway  enzyme  activity  and  
cardiac  progenitor  cell  availability  and  function  in  vivo  and  in  vitro. 
 
5.4  Activating  the  pentose  phosphate  pathway 
The  pentose  phosphate  pathway  is  most  well-known  for  its  role  in  
producing  NADPH  and  ribose  5-phosphate,  which  are  essential  in  
maintaining  cellular  redox  balance  and  DNA  repair.  However,  it  has  an  
important  additional  role  linked  to  G6PD  (refer  to  Figure  7).  G6PD,  the  
first  and  rate-limiting  enzyme  of  the  pentose  phosphate  pathway,  has  been  
associated  with  an  endogenous  survival  mechanism,  which  prevents  apoptosis  
and  promotes  angiogenesis.  This  will  be  described  after  a  brief  overview  of  
the  role  of  the  pentose  phosphate  pathway  in  regulating  cellular  redox  
balance. 
The  pentose  phosphate  pathway  is  the  principal  intracellular  source  
of  NADPH,  which  plays  a  vital  role  in  maintaining  cellular  redox  balance.  It  
has  a  dual  function  in  building  oxidative  capacity  and  producing  oxidative  
species  by  NADPH-dependent  enzymes  such  as  NADPH-oxidase.  The  
antioxidant  system,  composed  primarily  of  the  glutathione  system,  catalase  
and  superoxide  dismutase,  requires  NADPH  to  function.  Thus,  activation  of  
the  pentose  phosphate  pathway  may  attenuate  oxidative  stress  by  increasing  
antioxidant  capacity.  However,  the  opposite  may  also  be  true,  that  is,  
increased  pentose  phosphate  pathway  flux  may  enhance  ROS  production  by  
NAPDH  oxidase.  Of  note,  activation  of  the  pentose  phosphate  pathway  (via  
G6PD  activation),  has  been  linked  to  additional  effects  that  are  independent  
of  NADPH  production. 
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Increased  oxidative  stress  can  stimulate  G6PD  activity  in  rat  
cardiomyocytes,  leading  to  G6PD  translocation  to  the  plasma  membrane81.  
G6PD  is  necessary  for  phosphorylation  and  activation  of  VEGFR2, Akt and 
eNOS.  VEGFR2/Akt/eNOS  signaling  resulted  in  VEGF-stimulated  
angiogenesis82.  In  addition,  VEGFR2/Akt/Pim-1  signaling  induced  by  ischemia  
(via  activation  of  TK  and  G6PD)  was  associated  with  reduced  apoptosis.   
Therefore,  when  exposed  to  oxidative  stress  (associated  with  
hyperglycemia  or  ischemia),  cardiac  cells  may  activate  an  endogenous  
survival  mechanism  involving  G6PD  activation  and  translocation  to  the  cell  
membrane,  leading  to  VEGFR2/Akt  signaling.  This  would  act  to  maintain  
redox  status  (as  described  earlier),  promote  cell-survival  and  initiate  
restorative  angiogenesis.  In  support  of  this,  G6PD  overexpression  is  
associated  with  increased  NADPH  levels  and  improved  resistance  to  
oxidative  stress83,  while  partially  G6PD-deficient  mice  exhibit  increased  
cardiac dysfunction  following  ischemia-reperfusion81.  
This  mechanism  appears  to  be  compromised  in  diabetes;  however,  
benfotiamine  shows  promise  in  activating  and  restoring  it.  Thus,  
benfotiamine  may  have  therapeutic  potential  as  an  activator  of  the  pentose  
phosphate  pathway  and  G6PD/VEGFR2/Akt  pro-survival/pro-angiogenic  
signaling.  In  this  way,  benfotiamine  would  attenuate  oxidative  stress  
(associated  with  hyperglycemia  or  ischemia-reperfusion)  and  reduce  cell  
death. 
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5.5  Pharmacological  postconditioning 
Previous  work  by  our  group  showed  that  benfotiamine  administration  
at  the  onset  of  reperfusion  could  preserve  contractile  function  and  reduce  
infarct  size  in  response  to  ischemia-reperfusion.  Benfotiamine  may  have  
therapeutic  potential  as  a  pharmaceutical  postconditioning  agent  that  
activates  endogenous  survival  mechanisms  in  the  heart.  Therefore,  we  set  
out  to  investigate  this  by  assessing  the  cardioprotective  effects  of  acute  
benfotiamine  administration  and  the  involvement  of  the  PI3K/Akt  and  
JAK/STAT  signaling  pathways. 
 
6.  Summary 
Myocardial  infarction  is  a  major  cause  of  mortality  that  requires  
effective  treatment.  It  leads  to  cardiomyocyte  death,  which  is  associated  
with  contractile  dysfunction.  However,  the  heart  possesses  a  number  of  
endogenous  survival  mechanisms  that  it  can  activate  in  response  to  threats  
such  as  ischemia  and  hypoxia  (see  Figure  8).  These  include  signaling  via  the  
JAK/STAT  and  PI3K/Akt  pathways  (initiating  cell  survival  responses  
coordinated  by  the  nucleus  and  mitochondria)  and  activation  of  the  pentose  
phosphate  pathway  (associated  with  maintenance  of  redox  balance  and  
activation  of  pro-survival/pro-angiogenic  signaling).  Activation  of  these  
pathways  is  impaired  in  diabetes. 
Cell  death  due  to  myocardial  infarction  can  be  reduced  by  timeous  
reperfusion.  However,  the  initiation  of  reperfusion  can  itself  cause  cell    
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Figure  8:  SUMMARY  -  Endogenous  survival  mechanisms  in  myocardial  
infarction.  1)  Ischemia  can  result  in  cardiomyocyte  death,  which  2)  impairs  
contractile  function.  The  sooner  blood  flow  is  re-established,  the  larger  the  
proportion  of  the  myocardium  that  can  be  salvaged.  However,  3)  the  initiation  of  
reperfusion  can  itself  cause  cardiomyocyte  death.  When  confronted  with  a  threat,  
cells  4)  initiate  endogenous  survival  mechanisms,  such  as  5)  JAK/STAT3  and  
PI3K/Akt  signaling,  which  limit  cell  death  via  actions  at  the  nucleus  and  
mitochondrion.  These  survival  mechanisms  can  be  6)  impaired  by  diabetes  or  7)  
activated  by  postconditioning.  However,  8)  postconditioning  is  impaired  by  
comorbidities.  9)  Benfotiamine  may  act  as  a  pharmacological  postconditioning  
agent  that  reduces  cardiomyocyte  death  and  preserves  contractile  function.  
Abbreviations  JAK:  Janus  kinase,  PI3K:  phosphatidylinositol  3-kinase,  PPP:  pentose  
phosphate  pathway,  STAT:  signal  transducer  and  activator  of  transcription,  
VEGFR2:  vascular  endothelial  growth  factor  receptor  2.   
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death.  Postconditioning  is  able  to  attenuate  lethal  reperfusion  injury  via  
activation  of  JAK/STAT  and  PI3K/Akt  signaling.  However,  it  is  challenged  by  
limited  accessibility  and  the  impairment  of  its  effects  in  the  presence  of  
comorbidities.  A  pharmacological  agent  that  is  able  to  mimic  the  effects  of  
postconditioning  may  contribute  significantly  to  the  treatment  of  myocardial  
infarction.  We  propose  benfotiamine  as  a  potential  candidate. 
 
7.  Hypothesis 
Benfotiamine  protects  contractile  function  and  reduces  infarct  size  
when  administered  during  reperfusion  via  activation  of  the  PI3K/Akt  and  
JAK/STAT  signaling  pathways.   
 
8.  Aims 
I. To  determine  whether  benfotiamine  administration  at  the  onset  of  
reperfusion  is  associated  with  1)  improved  functional  recovery  and  2)  
reduced  infarct  size  in  response  to  ischemia-reperfusion 
 
II. To  test  whether  the  effects  of  benfotiamine  are  mediated  by  
activation  of  signaling  via  the  1)  PI3K/Akt  and/or  2)  JAK/STAT  
pathways  
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CHAPTER  THREE:  Materials  and  Methods 
 
 
 
 
We  proceeded  to  test  our  hypothesis  using  two  approaches.  In  part  
one  of  the  study,  Langendorff  isolated  heart  perfusions  with  regional  
ischemia  and  Evans  blue/triphenyltetrazolium  chloride  (TTC)  staining  were  
used  to  test  the  effect  of  benfotiamine  on  functional  recovery  and  infarct  
size  after  ischemia-reperfusion.  Inhibitors  of  the  PI3K/Akt  and  JAK/STAT  
pathways  were  employed  to  investigate  the  involvement  of  these  pathways  
in  mediating  benfotiamine‟s  effects. 
Part  two  of  the  study  involved  Langendorff  isolated  heart  perfusions  
with  global  ischemia,  which  were  performed  with  the  aim  of  producing  
tissues  that  had  been  subjected  to  varying  protocols.  These  tissues  were  
used  to  evaluate  the  effects  of  ischemia-reperfusion  and  benfotiamine  on  
PI3K/Akt  and  JAK/STAT  signaling  by  Western  blot  analysis. 
The  use  of  animals  and  experimental  procedures  in  the  study  were  
reviewed  and  approved  by  the  Animal  Research  Ethics  Committee  of  the  
Faculty  of  Natural  Sciences  at  Stellenbosch  University  [10NF_ESS01A]. 
Values  are  expressed  as  mean  ±  standard  error  of  the  mean  (SEM).  
Functional  data  were  analyzed  using  a  repeated  measures  analysis  of  
variance  (ANOVA)  with  a  Bonferroni  post-test.  Infarct  size  was  analyzed  
with  Tukey‟s  multiple  comparison  as  a  post-hoc  test.  P < 0.05  was  
considered  to  be  statistically  significant.  Analyses  were  done  with  GraphPad  
Prism,  version  5  (San  Diego,  California).  
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1.  Benfotiamine’s  effects  on  functional  recovery  and  infarct  size  -  the  
role  of  pro-survival  signaling 
The  first  part  of  the  study  involved  Langendorff  isolated  heart  
perfusions  with  regional  ischemia.  Functional  recovery  was  assessed  and  
Evans  blue/TTC  staining  was  used  to  evaluate  infarct  size  after  
ischemia-reperfusion.  Benfotiamine  was  administered  to  determine  its  effect  
on  functional  recovery  and  infarct  size.  Wortmannin,  a  PI3K  inhibitor,  and  
Tyrphostin  AG490,  a  JAK2  inhibitor,  were  used  to  investigate  the  
involvement  of  the  PI3K/Akt  and  JAK/STAT  signaling  pathways  in  mediating  
these  effects. 
 
1.1  Langendorff  isolated  heart  perfusions 
Male  Wistar  rats  (180-220 g)  were  euthanized  with  sodium  
pentobarbital  (100 mg/kg,  by  intraperitoneal  injection).  Hearts  were  rapidly  
excised  and  immersed  in  ice-cold  Krebs-Henseleit  buffer  to  establish  
hypothermic  cardioplegia,  thereby  preventing  ischemic  damage  before  
perfusion  could  be  established.  Retrograde  perfusion  was  initiated  via  
cannulation  of  the  aorta.  The  heart  was  perfused  at  constant  hydrostatic  
pressure  (100 cm H2O    75 mmHg)  with  Krebs-Henseleit  buffer,  equilibrated  
with  95%  O2  and  5%  CO2  (119.4 mM  NaCl,  24.9 mM  NaHCO3,  4.7 mM  
KCl,  1.2 mM  KH2PO4,  0.6 mM  MgSO4  7H2O,  0.6 mM  Na2SO4,  1.2 mM  CaCl2 
 2H2O,  11.0 mM  glucose).  The  temperature  of  the  heart  was  maintained  at  
37 ± 0.5ºC  by  means  of  a  temperature-controlled  water  jacket  and  
monitored  by  insertion  of  a  K-type  implantable  temperature  probe  into  the  
right  atrium.  
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1.2  Recording  functional  parameters 
A  fluid-filled,  latex  balloon  connected  to  a  pressure  transducer  was  
inserted  into  the  left  ventricle  and  adjusted  until  the  left  ventricular  end  
diastolic  pressure  was  5-15 mmHg.  Measurements  of  cardiac  function  
(diastolic  pressure,  systolic  pressure,  heart  rate,  dP/dt)  were  recorded  
throughout  using  ADInstrumentsTM  LabChart  Pro,  version  7  (New  South  
Wales,  Australia).  Coronary  flow  rate  (CFR)  was  measured  by  timed  
collection  of  coronary  effluent. 
Left  ventricular  developed  pressure  (LVDP)  was  obtained  by  
calculating  the  difference  between  left  ventricular  end  diastolic  pressure  and  
systolic  pressure.  The rate-pressure  product  (RPP)  was  calculated  by  
multiplying  heart  rate  with  systolic  pressure.  Hearts  that  failed  to  establish  
an  LVDP  of  at  least  50 mmHg  were  excluded  from  the  study. 
 
1.3  Experimental  protocol 
After  20  minutes  of  stabilization,  regional  ischemia  was  induced  by  
passing  a  3-0  silk  suture  around  the  left  anterior  descending  coronary  
artery  1-2  mm  below  the  intersection  of  the  pulmonary  conus  and  left  
atrial  appendage.  The  ends  of  the  suture  were  threaded  through  a  small  
plastic  tube  to  form  a  snare,  and  tightened.  After  30  minutes  of  ischemia,  
the  snare  was  released  to  initiate  reperfusion.  The  efficacy  of  ischemia  was  
confirmed  by  regional  cyanosis  and  a  significant  decrease  in  coronary  flow.  
Various  treatments  were  administered  for  the  first  20  minutes  of  
reperfusion.  
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Hearts  were  randomly  assigned  to  one  of  five  groups  (Figure  9):  
1.  Treatment control no  intervention 
2.  Benfotiamine 100 μM  benfotiamine 
3.  Vehicle  control 210-5 %  (v/v)  dimethyl  sulfoxide 
(DMSO) 
4.  Benfotiamine  +  Tyrphostin  AG490 100 μM  benfotiamine  and                 
0.1 μM  Tyrphostin  AG490 
5.  Benfotiamine  +  Wortmannin 100 μM  benfotiamine  and                 
0.1 μM  Wortmannin  
 
Wortmannin  and  Tyrphostin  AG490  were  obtained  from  ENZO  Life  
Sciences  (Mountain  View,  USA).  Both  treatments  were  dissolved  in  DMSO  
as  10 mM  stock  solutions  and  stored  at  -80ºC.  Wortmannin  and  AG490  
were  administered  dissolved  in  Krebs-Henseleit  buffer  with  a  final  
concentration  of  0.1 μM,  consistent  with  dosages  used  in  related  
studies34,84,85.  Group  4  experiments  were  carried  out  in  semi-darkness  with  
the  treatment  reservoir  and  tubing  covered  in  aluminium  foil  due  to  the  
light-sensitive  nature  of  Tyrphostin  AG490  .  Wortmannin  was  added  to  the  
buffer  immediately  before  administration  due  to  its  short  half-life  in  aqueous  
solution.  DMSO  did  not  exceed  210-5 %  (v/v).   
Benfotiamine  was  ordered  from  Sigma  Aldrich  (St.  Louis,  USA)  and  
administered  by  dissolving  it  in  Krebs-Henseleit  buffer.  A  concentration  of  
100 μM  was  selected  based  on  dose-response  curves  previously  conducted  
by  ourselves12  and  others64. 
All  treatments  were  dissolved  in  Krebs-Henseleit  buffer  to  the  
required  final  concentrations  on  the  day  of  the  experiment.  
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Figure  9:  Experimental  protocol  -  Part  one.  Hearts  underwent  regional  
ischemia  and  reperfusion  ±  benfotiamine  ±  Tyrphostin  AG490  or  Wortmannin.  
Abbreviations  Region  Isch:  regional  ischemia,  BFT:  benfotiamine,  DMSO:  dimethyl  
sulfoxide,  AG:  Tyrphostin  AG490,  WT:  Wortmannin.  
Stellenbosch University  http://scholar.sun.ac.za
38 
 
1.4  Determination  of  infarct  size 
Two  hours  of  reperfusion  were  allowed  to  ensure  wash-out  of  
dehydrogenase  enzymes  and  cofactors  from  non-viable  tissue.  At  the  end  of  
reperfusion,  the  left  anterior  descending  coronary  artery  was  re-occluded  by  
tying  the  suture  securely.  The  heart  was  infused  with  2 ml  of  2%  Evans  
Blue  dye  to  demarcate  the  area  at  risk  (i.e.  the  region  exposed  to  
ischemia-reperfusion).  The  heart  was  then  weighed  and  frozen  at  -4ºC  
overnight. 
On  the  following  day,  hearts  were  defrosted  slightly  and  cut  
transversely  into  four  2 mm  slices.  Slices  were  added  to  a  50 ml  Falcon  
tube  with  5 ml  1%  triphenyltetrazoilum  chloride  (TTC)  in  phosphate  buffer  
(pH  7.4)  and  incubated  at  37ºC  using  a  waterbath.  15-20  minutes  were  
allowed  for  the  tetrazolium  salt  to  react  with  dehydrogenase  enzymes  and  
cofactors  in  viable  tissue  to  form  a  formazan  pigment.  This  pigment  enabled  
living  tissue  (stained  deep  red)  to  be  distinguished  from  dead  tissue  
(pale-colored)  within  the  area  at  risk.  The  tubes  were  agitated  regularly  to  
ensure  even  exposure  to  TTC.   
After  TTC  staining,  slices  were  immersed  in  10%  formalin  for  20  
minutes  to  enhance  image  contrast,  before  being  scanned.  ImageJ,  version  
1.46r  (National  Institute  of  Health,  USA)  was  used  to  measure  the  area  at  
risk  (as  indicated  by  absence  of  Evans  blue  staining)  and  infarcted  area  (as  
indicated  by  a  lack  of  Evans  blue  and  TTC  staining).  Infarct  size  was  
expressed  as  a  percentage  of  the  area  at  risk.  
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2.  The  effects  of  ischemia  and  benfotiamine  on  pro-survival  signaling 
The  second  part  of  the  study  involved  Western  blot  analysis  to  
assess  activation  of  PI3K/Akt  and  JAK/STAT  signaling  in  response  to  
ischemia-reperfusion  and  benfotiamine.  In  order  to  produce  tissues  that  had  
been  exposed  to  ischemia  and  benfotiamine,  as  well  as  appropriate  controls,  
Langendorff  isolated  heart  perfusions  with  global  ischemia  were  performed.  
 
2.1  Langendorff  isolated  heart  perfusions 
Langendorff  isolated  heart  perfusions  were  carried  out  as  before  (see  1.1). 
 
2.2  Experimental  protocol 
After  90  minutes  of  stabilization,  global  ischemia  was  induced,  
followed  by  40  minutes  of  reperfusion.  A  shorter  reperfusion  period  was  
selected  than  in  our  previous  protocol,  since  the  tissues  were  used  for  
biochemical  analysis,  but  the  total  perfusion  periods  were  of  similar  length.  
Benfotiamine  was  administered  for  the  first  20  minutes  of  reperfusion. 
Hearts  were  randomly  assigned  to  one  of  four  groups  (Figure  10):   
1.  Non-ischemic  control not  exposed  to  ischemia 
2.  Non-ischemic  benfotiamine not  exposed  to  ischemia,               
100 μM  benfotiamine 
3.  Ischemic  control  30  minutes  of  global  ischemia 
4.  Ischemic  benfotiamine 30  minutes  of  global  ischemia,                  
100 μM  benfotiamine  
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Figure  10:  Experimental  protocol  -  Part  two.  Hearts  were  perfused  ±  
global  ischemia  and  ±  benfotiamine.  Abbreviations  Global  Isch:  global  ischemia,  
BFT:  benfotiamine.  
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At  the  end  of  reperfusion,  hearts  were  freeze-clamped  with  
Wollenberger  tongs  cooled  in  liquid  nitrogen  and  immersed  briefly  into  
liquid  nitrogen  until  frozen.  This  was  done  in  order  to  stop  metabolic  
activity  and  preserve  the  integrity  of  macromolecules.  Hearts  were  then  
divided  into  smaller  sections  and  stored  at  -80°C  for  biochemical  analysis. 
 
2.3  Protein  extraction 
Frozen  tissues  were  thawed  on  ice.  For  each  heart,  cytosolic  
proteins  were  isolated  from  some  sections  and  nuclear  proteins  were  
extracted  from  other  sections  (as  described  in  Appendix  A).  A  Bradford  
protein  assay  was  performed  to  determine  the  concentration  of  protein  in  
each  sample  (Appendix  B)  and  samples  were  prepared  for  Western  blot  
analysis  (Appendix  C). 
 
2.4  Western  blot  analysis 
In  order  to  assess  activation  of  JAK/STAT  signaling  in  response  to  
ischemia-reperfusion  and  benfotiamine  treatment,  we  used  STAT3  as  a  
marker.  Secondary  antibodies  for  STAT3  and  pSTAT3  (Tyr705)  (Cell  
Signaling  Technology)  were  used  to  assess  the  relative  quantities  of  these  
proteins  in  the  nucleus  and  cytosol.  We  calculated  the  ratio  of  pSTAT3  to  
STAT3  in  each  compartment.  Since  phosphorylation  of  STAT3  by  JAK2  
causes  activation  and  nuclear  localization16,  an  increased  pSTAT3/STAT3  
ratio  in  the  nucleus  would  imply  increased  JAK/STAT3  signaling.  
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To  assess  the  activation  of  PI3K/Akt  signaling  in  response  to  
ischemia-reperfusion  and  benfotiamine  treatment,  FOXO1  was  used  as  a  
marker.  Secondary  antibodies  for  FOXO1  and  pFOXO1  (Ser256)  (Cell  
Signaling  Technology)  were  used  to  assess  the  relative  quantities  of  these  
proteins  in  the  nucleus  and  cytosol.  We  calculated  the  ratio  of  pFOXO1  
to  FOXO  in  both  compartments.  Since  phosphorylation  of  FOXO1  by  Akt  
causes  deactivation  and  nuclear  export32,  an  increased  pFOXO1/FOXO1  
ratio  in  the  cytosol  would  suggest  increased  PI3K/Akt  signaling. 
Western  blot  analysis  was  carried  out  as  described  in  Appendix  D  
and  images  were  analyzed  using  ImageJ,  version  1.46r  (National  Institute  of  
Health,  USA).  
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CHAPTER  FOUR:  Results 
 
 
 
 
 
Functional  recovery 
As  shown  in  Table  1,  the  morphometric  characteristics  of  rats  were  
consistent  among  experimental  groups. 
 
Table  1:  Morphometric  characteristics  of  experimental  rats 
 
TCon:  Treatment  control,  BFT:  Benfotiamine,  VCon:  Vehicle  control,  BFT+AG:  
Benfotiamine  +  Tyrphostin  AG490,  BFT+WT:  Benfotiamine  +  Wortmannin.  Values  
are  mean  ±  SEM.   
 
We  investigated  benfotiamine‟s  effects  on  the  recovery  of  cardiac  
function  post-ischemia,  by  assessing  a  range  of  functional  parameters.  Values  
for  rate-pressure  product  (RPP)  and  dP/dt  before  and  after  ischemia  are  
shown  in  Table  2.  
 n Weight  (g) Heart  weight  (g) 
TCon 8 210.70 ± 2.9 1.15 ± 0.07 
BFT 8 204.44 ± 2.5 0.98 ± 0.03 
VCon 8 206.21 ± 3.0 0.97 ± 0.04 
BFT+AG 8 207.11 ± 3.4 1.03 ± 0.05 
BFT+WT 8 206.33 ± 3.4 1.04 ± 0.05 
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RPP,  an  indicator  of  cardiac  workload  or  oxygen  consumption,  was  
increased  at  the  onset  of  reperfusion  in  response  to  addition  of  Tyrphostin  
AG490  and  Wortmannin.  The  maximum  rate  of  increase  in  left  ventricular  
pressure,  dP/dt,  which  is  a  measure  of  contractility,  did  not  differ  between  
groups.   
 
Table  2:  Recovery  of  rate-pressure  product  and  dP/dt 
Baseline:  values  at  20-minute  time  point  during  stabilization,  Reperfusion:  values  
at  15-minute  time  point  during  reperfusion. TCon:  Treatment  control,  BFT:  
Benfotiamine,  VCon:  Vehicle  control,  BFT+AG:  Benfotiamine  +  Tyrphostin  AG490,  
BFT+WT:  Benfotiamine  +  Wortmannin.  Values  are  mean  ±  SEM.  1RPP:  rate-
pressure  product  (mmHg103/min),  2(mmHg103/sec).  Values  are  mean  ±  SEM.  
*p<0.05  vs.  treatment  control  at  the  same  time  point.  n=8. 
 
Left  ventricular  developed  pressure,  heart  rate  and  coronary  flow  
rate  are  shown  in  Figure  11.  No  significant  changes  were  seen  in  any  of  
these  parameters. 
  
 
Baseline   Reperfusion 
RPP1 +dP/dt2 RPP1 +dP/dt2_   
TCon 7975 ± 601.0 2875 ± 164.7 2215 ± 321.6 1567 ± 132.8 
BFT 5422 ± 1173 2423 ± 239.9 4128 ± 824.3 1554 ± 189.3 
VCon 7986 ± 839.6 3057 ± 324.3 8203 ± 677.0 2000 ± 467.9 
BFT+AG 10980 ± 3107 3414 ± 938.0 10780 ± 1118* 2555 ± 649.4 
BFT+WT 11820 ± 977.7 2966 ± 861.2 9368 ± 2719* 2764 ± 378.9 
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Figure  11:  Functional  recovery.  LVDP:  left  ventricular  developed  pressure,  HR:  
heart  rate,  CFR:  coronary  flow  rate,  VCon:  Vehicle  control,  BFT+AG:  Benfotiamine  
+  Tyrphostin  AG490,  BFT+WT:  Benfotiamine  +  Wortmannin.  
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Infarct  size 
Cell  death  was  assessed  by  means  of  Evans  blue/TTC  staining.  As  
shown  in  Figure  12,  the  area  at  risk  did  not  differ  between  groups,  
indicating  that  the  changes  observed  in  infarct  size  between  groups  were  
not  due  to  differences  in  the  size  of  the  region  exposed  to  ischemia. 
Benfotiamine  administration  led  to  a  decrease  in  infarct  size  from  
55.7 ± 5.0%  to  35.6 ± 2.4%  (p<0.05).  Inhibition  of  PI3K/Akt  signaling  by  
addition  of  Wortmannin  abrogated  this  infarct-limiting  effect  (35.6 ± 2.4%  vs.  
51.5 ± 1.3%,  p<0.05).  However,  inhibition  of  JAK/STAT  signaling  had  no  
significant  effect.  
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Figure  12:  Infarct  size.  TCon:  Treatment  control,  BFT:  Benfotiamine,  VCon:  
Vehicle  control,  BFT+AG:  Benfotiamine  +  Tyrphostin  AG490,  BFT+WT:  
benfotiamine  +  Wortmannin.  *P<0.05  vs.  TCon,  #P<0.05  vs.  BFT.  N=8.  
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Pro-survival  signaling 
Tissues  that  were  perfused  ±  ischemia-reperfusion  and  ±  benfotiamine  
administration  were  assessed  by  Western  blot  analysis.  pFOXO/FOXO  was  
assessed  in  the  cytosol  as  an  indication  of  PI3K  signaling.  pSTAT3/STAT3  
was  assessed  in  the  nucleus  as  an  indication  of  JAK/STAT3  signaling.  A  
sample  size  of  four  was  used.  
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PI3K/Akt  signaling  as  assessed  by  pFOXO/FOXO 
As  seen  in  Figure  13,  the  ratio  of  pFOXO/FOXO  increased  in  ischemic  
hearts  treated  with  benfotiamine.  Ischemia  or  benfotiamine  exposure  had  no  
significant  effect  on  their  own.  
 
 Figure  13:  pFOXO/FOXO  in  the  cytosol.  CN  Non-ischemic  control,  BN:  
Non-ischemic  benfotiamine,  CI:  Ischemic  control,  BI:  Ischemic  benfotiamine.  
Cytosol 
82 kDa 
45 kDa 
FOXO 
pFOXO 
ß-actin 
78-82 kDa 
* 
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JAK/STAT  signaling  as  assessed  by  pSTAT3/STAT3 
The  effects  of  ischemia  and  benfotiamine  treatment  on  pSTAT3/STAT3        
in  the  nucleus  are  depicted  in  Figure  14.  There  were  no  significant  
changes. 
 
Figure  14:  pSTAT3/STAT3  in  the  nucleus.  CN  Non-ischemic  control,  BN:  
Non-ischemic  benfotiamine,  CI:  Ischemic  control,  BI:  Ischemic  benfotiamine.  
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pSTAT3 
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CHAPTER  FIVE:  Discussion 
 
 
 
 
Benfotiamine’s  effect  on  functional  recovery  and  infarct  size  -        
the  role  of  pro-survival  signaling 
Contractile  function 
We  assessed  the  effects  of  acute  benfotiamine  administration  (at  the  
onset  of  reperfusion)  on  functional  recovery  of  the  rat  heart.  Inhibitors  of  
PI3K/Akt  or  JAK/STAT  signaling  were  administered  in  addition  to  
benfotiamine,  to  investigate  a  role  for  these  pathways  in  mediating  
benfotiamine‟s  effects.  With  the  exception  of  an  increased  rate-pressure  
product  in  response  to  Tyrphostin  AG490  or  Wortmannin  administration,  
no  significant  differences  were  found  in  any  of  the  functional  parameters  
assessed.  This  is  in  contrast  to  a  number  of  related  studies. 
The  effects  of  benfotiamine  on  cardiac  contractile  function  were  first  
investigated  in  a  study  by  Ceylan  Isik  et  al.76  Two  weeks  of  benfotiamine  
administration  reduced  contractile  dysfunction  in  cardiomyocytes  isolated  
from  streptozotocin-induced  diabetic  mice.  A  second  study,  by  Katare  et  
al77,  found  that  8  or  16  weeks  of  benfotiamine  supplementation  improved 
diastolic  and  systolic  function  in  streptozotocin-induced type 1 or 
leptin-receptor  mutant  type  2  diabetic  mice.  In  a  third  study,  performed  by  
the  same  laboratory13,  6  weeks  of  benfotiamine  supplementation  significantly  
attenuated  functional  deterioration  of  hearts  after  myocardial  infarction  in  
both  non-diabetic  and  diabetic  mice.  In  each  of  these  studies,  benfotiamine  
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was  administered  by  chronic  supplementation,  unlike  in  the  present  study,  
which  involved  acute  benfotiamine  administration. 
A  recent  study,  performed  by  our  own  laboratory12,  also  made  use  
of  acute  benfotiamine  administration  at  the  onset  of  reperfusion.  An  
increase  in  the  recovery  of  LVDP  after  global  ischemia  and  reperfusion  
were  induced  by  20  minutes  of  benfotiamine  administration.  In  comparison,  
the  lack  of  significant  changes  seen  in  the  present  study,  may  be  related  to  
the  specific  protocols  employed  (regional  ischemia,  as  opposed to  global  
ischemia  as  in  our  previous  study). 
To  summarize,  in  the  current  study  acute  benfotiamine  administration  
at  the  onset  of  reperfusion  after  regional  ischemia  did  not  lead  to  
significant  changes  in  functional  recovery  between  groups.  This  may  suggest  
that  the  time  of  benfotiamine  exposure  and  the  extent  of  ischemia  were  
not  severe  enough  to  allow  for  marked  differences  between  groups  in  the  
functional  parameters  assessed. 
 
Cell  death 
The  effect  of  benfotiamine  on  cardiac  cell  death  was  initially  
examined  in  the  context  of  diabetic  cardiomyopathy.  In  Katare‟s  study77  
with  streptozotocin-induced  type  1  or  leptin  receptor-mutant  type  2  
diabetic  mice,  benfotiamine  supplementation  was  also  linked  to  prevention  
of  cardiomyocyte  death.  This  pro-survival  effect  was  concomitant  with  the  
restoration  of  Akt/Pim-1  signaling  and  levels  of  pBad  and  Bcl-2,  as  well  as  
the  restoration  of  STAT3-induced  Pim-1  expression  and  the  modification  of  
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Pim-1  downstream  effectors.  This  suggests  that  benfotiamine‟s  anti-apoptotic  
effects  may  be  mediated  by  signaling  via  Akt,  STAT3  and  Pim-1. 
In  vitro  experiments  demonstrated  that  benfotiamine  administration  
could  also  counteract  hyperglycemia-induced  reductions  in  the  levels  of  
pSTAT3,  pAkt,  peNOS,  and  pFOXO,  as  well  as  Akt  activity  and  nuclear  
localization.  Of  note,  inhibition  of  PI3K  and  Akt  abrogated  Benfotiamine‟s  
anti-apoptotic  effect,  but  STAT3  inhibition  had  no  effect  on  apoptosis.  
Authors  suggest  that  the  induction  of  pAkt  by  benfotiamine  may  have  
compensated  for  STAT3  inhibition. 
Additional  studies  found  that  benfotiamine  supplementation  reduced  
cardiomyocyte13  and  cardiac  progenitor  cell  apoptosis80.  In  both  cases,  G6PD  
and  VEGFR2  were  involved,  in  addition  to  Akt,  Pim-1,  Bad  and  Bcl-2,  in  
agreement  with  the  previous  study73. 
As  previously  discussed,  these  studies  made  use  of  chronic  
benfotiamine  supplementation.  However,  earlier  findings  from  our  laboratory  
using  acute  benfotiamine  administration  were  in  accordance  with  these  
studies12.  A  reduction  in  infarct  size  was  observed  under  hyperglycemic  and  
normoglycemic  conditions.  This  compelled  us  to  investigate  the  underlying  
mechanisms  of  this  effect. 
In  the  current  study,  benfotiamine  was  administered  with  and  
without  inhibitors  of  the  PI3K/Akt  and  JAK/STAT  pathways.  Acute  
benfotiamine  administration  at  the  onset  of  reperfusion  decreased  infarct  
size  from  55.7 ± 5.0%  to  35.6 ± 2.4%.  This  effect  was  counteracted  by  
inhibition  of  PI3K/Akt  but  not  inhibition  of  JAK/STAT  signaling.  Thus  the  
infarct-sparing  effects  of  benfotiamine  may  not  depend  on  JAK/STAT  
signaling,  but  appears to  be  mediated  by  PI3K/Akt. 
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A  reduction  in  infarct  size  is  expected  to  be  accompanied  by  an  
improvement  in  functional  recovery.  However  this  is  not  always  the  case  
since  the  cells  that  were  salvaged  may  not  return  to  normal  functioning  
immediately.  Furthermore,  a  study  by  Lochner  et  al.86  found  that  infarct  size  
is  a  more  reliable  endpoint  than  functional  recovery.  Therefore  the  
contrasting  results  from  our  functional  recovery  and  infarct  size  
measurements  are  not  necessarily  contradictory. 
However,  the  increase  in  infarct  size  caused  by  administering  
Wortmannin  in  addition  to  benfotiamine,  does  not  necessarily  indicate  
attenuation  of  benfotiamine-induced  cardioprotection.  Increased  cell  death  as  
result  of  PI3K  inhibition  may  also  be  related  to  attenuation  of  endogenous  
survival  PI3K/Akt  signaling  (independent  of  activation  by  benfotiamine).  
Therefore,  we  used  an  additional  approach  to  test  this  finding. 
 
The  effects  of  ischemia  and  benfotiamine  on  pro-survival  signaling 
PI3K/Akt  signaling 
In  the  current  study,  an  increase  in  pFOXO/FOXO  was  found  in  
the  cytosol  in  response  to  benfotiamine  treatment  following  ischemia.  An  
increase  in  PI3K/Akt  signaling  is  associated  with  FOXO  phosphorylation  and  
nuclear  export.  Therfore,  this  suggests  that  in  ischemic  hearts,  benfotiamine  
treatment  activated  PI3K/Akt  signaling.  Benfotiamine  had  no  effect  on  
non-ischemic  tissue,  while  ischemia  had  no  significant  effect  on  untreated  
tissue  i.e.  ischemia  or  benfotiamine  treatment  in  isolation  was  insufficient  to   
activate  PI3K/Akt  signaling.  However,  in  ischemic,  treated  hearts,  these  
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stimuli  may  have  acted  synergistically  to  initiate  PI3K/Akt  signaling,  an  
endogenous  survival  mechanism  in  the  heart. 
Other  studies  have  found  increased  Akt  phosphorylation  in  response  
to  ischemia9  or  chronic  benfotiamine  administration13,77,80.  These  findings  are  
corroborated  by  two  studies  in  non-cardiac  tissues.  Gadau  et  al.87  reported  
that  4  weeks  of  benfotiamine  administration  leads  to  Akt-mediated  pro-
survival  and  pro-angiogenic  effects  in  ischemic  diabetic  mouse  limbs.  
Furthermore,  in  a  study  by  Marchetti  and  colleagues88,  benfotiamine  
administration  restored  endothelial  progenitor  cell  proliferation  via  activation  
of  Akt/FOXO1  signaling. 
Therefore,  20  minutes  of  benfotiamine  administration  at  the  onset  of  
reperfusion  may  reduce  infarct  size  via  activation  of  PI3K/Akt  signaling. 
 
JAK/STAT  signaling 
We  did  not  find  activation  of  JAK/STAT3  signaling  in  response  to  
ischemia  in  our  study.  Increased  JAK/STAT3  signaling  has  been  found  by  
others  in  response  to  ischemia  and  reperfusion  in  isolated  rat  hearts89.  
However,  heart  tissue  was  obtained  at  the  end  of  a  two-hour  reperfusion  
period,  in  contrast  to  our  study  where  tissues  were  obtained  at  the  
40-minute  time  point  during  reperfusion. 
Furthermore,  we  found  that  benfotiamine  administration  did  not  
increase  JAK/STAT3  signaling  at  the  40-minute  time  point  during  
reperfusion.  Benfotiamine may  not  activate  JAK/STAT3  under  these  
conditions  or  its  activation  may  be  transient.  In  addition,  the  fact  that  
Tyrphostin  AG490  administration  had  no  significant  effect  on  infarct  size,  
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may  be  because  STAT3  activation  has  effects  which  are  not  fully  realized  in  
the  time  duration  or  context  of  our  study.   
Using  tissues  obtained  at  a  number  of  other  time  points  during  
reperfusion  (such  as  10,  15,   20  and  60  minutes)  in  addition  to  those  
obtained  at  the  40-minute  time  point,  may  add  valuable  insight. 
Katare  et  al.  found  STAT3  activation  in  the  response  to  chronic  
benfotiamine  supplementation  in  the  context  of  diabetic  cardiomyopathy77.  
Benfotiamine  also  reduced  hyperglycemia-induced  apoptosis,  but  this  effect  
was  not  abrogated  by  STAT3  inhibition.  Thus,  benfotiamine  activation  in  the  
heart  in  response  to  benfotiamine  administration  may  be  time-  and/or  
context-dependent,  leading  to  effects  that  may  not  directly  reduce  apoptosis.   
Alternatively,  since  the  increase  in  STAT3  activation  in  diabetic,  
treated  mice  during  their  study  did  not  exceed  levels  in  the  non-diabetic  
mice,  benfotiamine  may  have  simply  restored  normal  STAT3  activation  by  
reducing  hyperglycemia-related  perturbations.  In  comparison,  Akt  and  FOXO  
activation  levels  in  the  diabetic,  treated  mice  did  exceed  levels  in  the  
non-diabetic  group.  The  inclusion  of  a  control  group  with  non-diabetic,  
benfotiamine-treated  mice  would  have  allowed  for  comparison  of  STAT3  
activation  with  non-diabetic,  untreated  mice.   
 
Conclusion 
Currently  available  evidence  suggests  that  chronic  benfotiamine  
supplementation  reduces  apoptosis  in  the  heart,  by  activating  PI3K/Akt  
signaling,  an  endogenous  survival  mechanism.  This  study  found  that  this  
effect  may  also  be  induced  by  acute  benfotiamine  administration  at  the  
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onset  of  reperfusion  following  ischemia.  These  effects  deserve  further  
investigation  since  acute  benfotiamine  administration  may  have  clinical  
applicability  as  a  pharmacological  postconditioning  agent.  
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Appendix  A:  Protein  Extraction  from  Tissue 
 
 
MATERIALS  AND  EQUIPMENT 
Tweezers 
Aluminium  foil 
Liquid  nitrogen 
Mortar  and  pestle 
Modified  radioimmuno-precipitation  (RIPA)  buffer 
Tissue  homogenizer 
Homogenizing  tubes 
Micro-centrifuge 
Vortex 
Buffer  A 
Buffer  B 
 
PREPARING  REAGENTS 
100 ml  modified  RIPA  buffer 
50 mM Tris-HCl buffering  agent,  prevents  protein  denaturation 
1%   Nonidet-P40 non-ionic  detergent  to  extract  proteins,  10%   
stock  solution  in  H2O 
0.25%   Sodium ionic  detergent  to  extract  proteins,  10%  stock   
 deoxycholate solution  in  H2O,  protect  from  light  
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1 mM   Phenylmethyl- cholinesterase  inhibitor/serine  and  cysteine   
 sulfonyl  fluoride protease  inhibitor,  200 mM  stock  solution  in 
 (PMSF) isopropanol,  store  at  room  temperature 
1 mM EDTA calcium  chelator,  100 mM  stock  solution  in  
H2O,  pH  7.4 
1 µg/ml   Leupeptin store  frozen  in  aliquots,  1 mg/ml  in  H2O 
1 mM   Activated tyrosine  protein  phosphatase  inhibitor,  200 mM 
 Na3VO4  stock  solution  in  H2O 
1 mM   Sodium  serine/threonine  protein  kinase  inhibitor,      
 flouride 200 mM  stock  solution  (room  temperature) 
4 µg/ml   Soyabean   1 mg/ml  in  0.01 M  phosphate  buffer,  pH  6.5 
 trypsin  inhibitor   with  0.15 M  NaCl  (freeze  aliquots  at  -20ºC) 
1 mM   Benzamidine 200 mM  stock  solution  dissolved  in  dH2O  –  
store  at  -200C 
 
I. Add  790 mg  Tris  base  to  75 ml  dH2O.  Add  900 mg  NaCl  and  stir  
until  solids  are  dissolved.  Using  HCl,  adjust  the  pH  to  7.4 
II. Add  10 ml  of  10%  Nonidet-P40  to  the  solution 
III. Add  2.5 ml  of  10%  Na-deoxycholate  and  stir  until  solution  is  clear 
IV. Add  1 ml  of  100 mM  EDTA  to  the  solution.  Adjust  the  volume  of  
the  solution  to  100 ml  using  a  graduated  cylinder.  Aliquot  and  store  
at  2-8°C 
V. On  the  day,  add  the  remaining  protease,  phosphatase  and  trypsin  
inhibitors  (100 µl  of  leupeptin,  500 µl  of  PMSF,  Na3VO4,  benzamidine,  
sodium  flouride  and  soyabean  trysin  inhibitor).  PMSF  should  be  
added  immediately  before  use  due  its  short  half-life  in  aqueous  
solution  (approximately  30  minutes)  
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100  x  HEPES  stock  solution  (100mM) 
Dissolve  0.100 g  HEPES  in  100 ml  dH2O.  pH  to  7.9  on  ice  and  store  at  
4ºC 
 
100  x  Buffer  A  (hypotonic  buffer)  stock  solution 
• 150 mM  MgCl2 
• 1 M  KCL 
• 50 mM  dithiothreitol 
• 20 mM  PMSF 
 
Make  up  in  1 L  with  dH2O  and  store  at  4ºC 
 
100  x  Buffer  B  (high  salt  buffer)  stock  solution 
• 25%  glycerol   
• 42 M  NaCl 
• 150 mM  MgCl2 
• 20 mM  EDTA 
• 50 mM  dithiothreitol 
• 20 mM  PMSF 
 
Working  solutions  of  Buffers  A  and  B 
Buffer  A:   add  10 ml  Buffer  A  stock  and  1 ml  HEPES  stock  solution,  
make  up  to  50 ml  with  dH2O  in  a  Falcon  tube  and  store  at  
4ºC 
Buffer  B:   add  10 ml  Buffer  B  stock  and  2 ml  HEPES  stock  solution,  
make  up  to  50 ml  with  dH2O  Falcon  tube  and  store  at  4ºC  
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METHOD 
I. Use  tweezers  to  wrap  each  piece  of  tissue  sample  in  a  square  of  
aluminium  foil  (with  foil  folded  4  times)  and  place  in  liquid  nitrogen 
II. Use  a  mortar  and  pestle  to  pulverise  the  frozen  sample  under  liquid  
nitrogen,  producing  a  powder  that  is  amenable  to  homogenization 
III. Carefully  unwrap  the  foil  and,  keeping  cold,  transfer  the  powdered  
tissue  into  tubes  containing  RIPA  buffer  –  aim  to  make  homogenates  
that  are  one  third  tissue  and  two  thirds  lysis  buffer 
IV. Homogenize  tissues  using  a  tissue  homogenizer 
V. Transfer  the  homogenates  to  fresh,  pre-chilled  Eppendorf  tubes  and  
keep  on  ice 
 
FOR  CYTOSOLIC  FRACTION 
VI. Centrifuge  homogenates  at  12000 rpm  for  15  minutes  at  4ºC 
VII. Transfer  the  supernatants  (protein  lysates)  to  fresh,  pre-chilled  
Eppendorf  tubes  and  store  at  -80ºC 
 
FOR  NUCLEAR  EXTRACT   
VI. Bring  homogenates  to  the  cold  room  and  centrifuge  for  10  seconds  
on  the  highest  setting 
VII. Decant  supernatant  and  resuspend  pellet  in  400 µL  cold  Buffer  A 
VIII. Leave  on  ice  for  10  minutes  to  swell 
IX. Vortex  for  10  seconds  and  centrifuge  for  10  seconds 
X. Discard  supernatant  and  resuspend  pellet  in  100 µL  cold  Buffer  B 
XI. Leave  for  2  minutes  on  ice  and  centrifuge  for  2  minutes 
XII. Transfer  the  supernatant  to  fresh,  pre-chilled  Eppendorf  tubes  and  
store  at  -80ºC  
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Appendix  B:  Bradford  Protein  
Determination 
 
 
 
 
MATERIALS  AND  EQUIPMENT 
Bovine  serum  albumin  (BSA) 
Bradford  reagent 
Spectrophotometer 
 
PREPARING  REAGENTS 
5  x  Bradford  reagent  stock  solution 
• Dilute  500 mg  Coomassie  brilliant  blue  G250  in  250 ml  95%  ethanol 
• Add  500 ml  phosphoric  acid,  mix  thoroughly 
• Adjust  the  volume  to  1 L  with  dH2O 
• Filter  solution  and  store  at  4ºC  protected  from  light  
 
Bradford  reagent 
• Dilute  stock  solution  with  dH2O 
• Filter  with  two  sheets  of  filter  paper  (solution  is  red/brown  and  
turns  blue  when  binding  to  protein)  
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METHOD 
• Switch  on  the  spectrophotometer  in  advance  to  allow  time  for  it  to  
calibrate 
• Thaw  BSA  stock  solution  (200 µg/ml,  stored  at  -20 ºC)  and  the  
protein  samples  on  ice  (keep  on  ice  throughout) 
• Mark  7  tubes  for  the  protein  standards  and  2  for  each  sample 
• Prepare  a  dilution  series  as  follows: 
  
 
• For  each  sample,  place  95 µl  dH2O  and  5 µl  of  protein  sample  in  
duplicate  Eppendorf  tubes 
• Vortex  tubes  briefly 
• Add  900 µl  Bradford  working  solution  to  each  tube  and  vortex  again 
• Incubate  tubes  at  room  temperature  for  5  minutes 
• Set  the  spectrophotometer to  595 nm  and  read  absorbances  of  
standards  and  samples  
BSA dH2O Conc. 
0 100 µl Blank 
10 µl 90 µl 2 µg 
20 µl 80 µl 4 µg 
40 µl 60 µl 8 µg 
60 µl 40 µl 12 µg 
80 µl 20 µl 16 µg 
100 µl 0 µl 20 µg 
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•  If  absorbance  of  samples  falls  outside  the  range  of  the  highest  
standard,  dilute  with  RIPA  buffer  and  read  again 
• In  Microsoft  Excel,  plot  the  absorbance  values  against  the  protein  
concentrations  in  µg  to  generate  a  standard  curve 
• Calculate  the  protein  concentration  of  each  sample  and  how  much  
should  be  loaded  into  each  well  to  have  50 µg  of  protein  per  well  
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Appendix  C:  Sample  Preparation 
 
 
 
 
MATERIALS  AND  EQUIPMENT  
Heating  block 
Laemmeli  sample  buffer 
Sharp  instrument 
Vortex  
Centrifuge 
 
PREPARING  REAGENTS 
Laemmeli  sample  buffer  stock  solution 
3.8 ml  dH2O 
1.0 ml  Tris-HCl,  pH  6.8 
0.8 ml  glycerol 
1.6 ml  10%  SDS 
0.4 ml  0.05%  bromophenol  blue  
Stellenbosch University  http://scholar.sun.ac.za
77 
 
METHOD 
I.  Set  the  heating  block  to  95ºC  to  allow  time  for  it  to  heat  up 
II.  Make  up  a  working  solution  of  sample  buffer  by  combining  850 µL  
Laemmeli  stock  solution  with  150 µL  ß-mercaptoethanol  and  vortexing  
(work  in  the  fume  hood) 
III. Label  tubes  for  each  sample 
IV. Add  a  quantity  of  sample  buffer  equal  to  one  third  of  the  total  
sample  volume  (i.e.  half  the  volume  of  protein  which  you  will  add)  
to  each  tube  as  calculated  after  Bradford  protein  determination 
V. Add  the  correct  quantity  of  protein  to  each  tube 
VI.  Punch  holes  in  the  lid  of  each  tube  using  the  sharp  instrument  and  
place  on  the  heating  block  for  5  minutes 
VII.  Vortex  each  sample  and  centrifuge  for  20  seconds 
VIII. Load  protein  marker  and  samples  onto  gel  
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Appendix  D:  Western  Blot  Analysis   
with  Precast  Gels 
 
 
 
 
MATERIALS  AND  EQUIPMENT  
Mini-Protean  tetra  cell  tank 
Electrophoresis  module 
Powerpac  power  supply 
Mini-Protean  pre-cast  gels 
Electrophoresis  buffer 
Protein  marker 
Biorad  Transfer  Blot 
Transfer  packs 
Ponceau  S  staining  solution 
Tris-buffered  saline-tween  (TBS-T) 
Non-fat  milk  powder  or  bovine  serum  albumin  (BSA) 
Primary  antibody 
Rotator  (at  4ºC) 
Horseradish  peroxidase-linked  secondary  antibody  
Rotator  (at  room  temperature)   
Enhanced  chemiluminescent  (ECL)  reagent 
Biorad  Chemidoc 
NaOH  
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DAY  ONE 
PREPARING  REAGENTS 
10  x  TBS  stock  solution 
• 48.4 g  Tris 
• 160 g  NaCl 
 
Dissolve  in  800 ml  dH2O,  adjust  pH  to  7.6  with  concentrated  HCl  and  
make  up  to  2 L.  Store  at  4ºC  until  needed 
 
TBS-T  working  solution 
Add  200 ml  of  10  x  TBS  stock  solution  to  a  2 L  Schott  bottle  and  fill  
with  dH2O.  Add  2 ml  of  tween 
 
10  x  Electrophoresis  buffer  stock  solution 
• 60.6 g  Tris base 
• 288 g  Glycine   
• 20 g  SDS  (10%) 
 
Dissolve  in  2 L  dH2O.  Store  at  4ºC  until  needed.  
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GEL  ELECTROPHORESIS 
I. Remove  comb  by  positioning  both  thumbs  on  the  ridges  of  the  
comb  and  pushing  upwards  in  one  smooth  continuous  motion 
II. Gently  remove  the  green  tape  at  bottom  of  gel  cassette 
III. Rinse  wells  with  electrophoresis  buffer  using  an  insulin  syringe,  
syringe  wash  bottle  or  disposable  transfer  pipette 
IV. Set  the  electrode  assembly  to  the  open  position  on  a  clean  flat  
surface 
V. Place  the  gel  cassettes,  short  plate  facing  inwards,  onto  the  gel  
supports.  Note  that  the  gel  will  now  rest  at  a  30º  angle,  tilting  
away  from  the  center  of  the  electrode  assembly.  If  an  odd  number  
of  gels  are  to  undergo  electrophoresis,  use  the  buffer  dam  to  
complete  the  assembly 
VI. While  gently  keeping  the  gel  cassettes  against  the  green  gaskets,  
slide  the  green  arms  of  the  clamping  frame  over  the  gels,  locking  
them  into  place 
VII. Fill  the  buffer  dam  with  electrophoresis  buffer 
VIII. Carefully  load  the  samples  and  an  appropriate  protein  marker 
IX. Place  the  plate  assembly  into  the  gel  tank  and  fill  with  
electrophoresis  buffer  (700 ml  for  2  gels  or  1000 ml  for  4  gels) 
X. Electrophorese  gel  at  99 V  until  the  dye  front  reaches  the  line  on  
the  bottom  of  the  gel  cassette  (±  1  hour) 
XI. Disconnect  the  cell  and  remove  the  cassette  by  aligning  the  arrow  
on  the  opening  key  with  the  arrows  marked  on  the  casette  and  
applying  downward  pressure.  Remove  gel  gently  
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PROTEIN  TRANSFER 
I. Open  the  transfer  pack  and  place  the  blotting  paper  marked  
“Bottom”  into  the  Biorad  Transfer  Blot  cassette.  Place  the  gel  on  
top  followed  by  the  blotting  paper  marked  “Top”.  Ensure  that  the  
membrane  faces  the  gel.  Smooth  out  bubbles  with  the  roller 
II. Place  lid  on  top  and  lock  in  place 
III Place  the  cassette  in  the  Biorad  Transfer  Blot  and  set  to  transfer  
for  7-12  minutes,  depending  on  the  size  of  the  protein  of  interest 
IV. Check  that  protein  has  transferred  and  then  rinse  once  with  TBS-T   
V. Pour  Ponceau  S  staining  solution  on  top  and  swirl  until  red  bands  
appear  strongly 
VI Pour  off  the  stain  and  rinse  with  dH2O  until  membrane  is  clear 
VII Place  membrane  between  two  transparencies,  and  scan  in  the  
membrane  on  computer  to  use  Ponceau  S  as  a  loading  marker 
 
BLOCKING  AND  INCUBATING  WITH  PRIMARY  ANTIBODY 
I. Rinse  membrane  3  x  5  minutes  with  TBS-T 
II. Block  for  1  hour  in  5%  non-fat  milk  powder  or  1%  BSA,  made  up  
in  TBS-T 
III. Wash  3  x  5  minutes  in  TBS-T 
IV. Place  membrane  in  a  50 ml  Falcon  tube  containing  5 µL  of  primary  
antibody  in  5 ml  of  TBS-T  (i.e.  a  1  in  1000  concentration) 
V. Place  on  rotator  in  4ºC  walk-in  fridge  overnight  
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DAY  TWO 
INCUBATING  WITH  SECONDARY  ANTIBODY 
I. Remove  membrane  from  primary  antibody 
II. Wash  3  x  5  minutes  in  TBS-T 
III. Place  membrane  in  a  50 ml  Falcon  tube  containing  1 µL  of  secondary  
antibody  in  5 ml  of  TBS-T  (i.e.  a  1  in  5000  concentration) 
IV. Place  on  rotator  at  room  temperature  for  1  hour 
V. Wash  membrane  3  x  5  minutes  in  TBS-T 
 
PROTEIN  VISUALIZATION  AND  IMAGE  ANALYSIS 
I. Prepare  ECL  by  combining  reagents  A  and  B  in  a  1:1  ratio  in  a  
foil-covered  tube.  Add  1 ml  to  membrane,  covering  surface  
completely  by  tilting  gently 
II. After  2  minutes,  transfer  the  membrane  to  the  tray  of  the  Biorad  
Chemidoc 
III. Select  the  “Image  Lab”  program  from  the  computer‟s  desktop 
IV. The  start  page  will  pop  up  –  choose  an  existing  protocol  or  create  
a  new  one.  Modify  protocol  settings  as  required  by  selecting  the  
relevant  item  under  “Protocol  Set  Up” 
V. Select  the  “Gel  Imaging”  option  and  make  a  selection  in  the  
“Application”  section  using  the  “Select”  button. 
VI. Select  “Protein  Gels”  from  the  drop-down  menu  and  choose  the  
applicable  option,  for  example  “Ponceau”.  The  appropriate  required  
filter  and  illumination  settings  will  appear  
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VII. Set  the  “Imaging  area”  to  „Biorad  Criterion  Gel”.  The  imaging  area  
will  be  displayed  on  the  right  hand  side 
VIII. Specify  the  optimum  exposure,  for  example,  “Intense  Bands”.  Default  
color  is  auto-selected 
IX. Select  “Lane  and  Band  Detection”  to  do  molecular  weight  analysis 
X. Select  the  required  level  of  sensitivity 
XI. Select  “Analyze  MW”  then  select  molecular  standard  used,  the  lane  
it  is  in  and  the  regression  method  “Linear  (semi-log)” 
XII. Select  “Generate  a  report”  –  specific  output  and  name  it 
XIII. Get  a  protocol  summary  and  save  it 
XIV. Load  the  gel  into  the  imager  and  click  on  the  “Position  Gel”  
button.  A  live  image  of  the  gel  appears,  allowing  you to  adjust  its  
position  and  the  zoom  setting  as  required 
XV. Click  on  “Run  Protocol”.  When  the  images  and  report  appear,  save  
to  an  appropriately  labeled  folder 
 
STRIPPING  AND  REPROBING 
I. Wash  membrane  2  x  5  minutes  with  dH2O 
II. Strip  membrane  by  washing  with  0.2 M  NaOH  for  5  minutes 
III. Wash  membrane  2  x  5  minutes  with  dH2O 
IV. Block  for  1  hour  in  5%  non-fat  milk  powder  or  1%  BSA  made  up  
in  TBS-T  
V Wash  3  x  5  minutes  in  TBS-T 
VI. Proceed  with  normal  Western  blot  procedure  (incubating  with  
primary  antibody  overnight) 
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